Enzymatic deiodination of thyroid hormones by Schoenmakers, C.H.H. (Christian)
ENZYMATIC DEIODINATION OF THYROID HORMONES 
(ENZYMATISCHE DEJODERING VAN SCHILDKLIERHORMONEN) 
PROEFSCHRIFT 
Ter verkrijging van de graad van doctor 
aan de Erasmus Universiteit Rotterdam 
op gezag van de Rector Magnificus 
Prof. Dr. P.W.C. Akkermans M. Lit. 
en volgens besluit van hel COllege voor Promoties. 
De openbare verdediging zal plaatsvinden op 
woensdag 14 september 1994 om 11.45 UUL 
door 
Christianus Hermann Hendrikus Schoemnakers 
geboren te Oss 
PROMOTIECOMMISSIE 
PROMOTOR: Prof.Dr.Ir. T.J. Visser 
OVERJGE LEDEN: Prof.Dr. G. Hermemann 
Prof. Dr. J .A. Grootegoed 
Prof. Dr. J.J.M. de Vijlder 
(Erasmus Universiteit Rotterdam) 
(Erasmus Universiteit Rotterdam) 
(Erasmus Universiteit Rotterdam) 
(Universiteit van Amsterdam) 
The studies reported iu this thesis were carried out under the direction of Prof.Dr.Ir 
T.J. Visser in the laboratory of the Thyroid Hormone Research Unit (head Prof.Dr. 
G. Hermemann) of the Department of Internal Medicine III and Clinical 
Endocrinology (head Prof.Dr. J.C. Birkenhilger), Erasmus University Medical 
School, Rotterdam, The Netherlands. 
This work was supported by the Netherlands Organization for Scientific Research 
(NWO). 
Zomergras, 
van dappere krijgsmansdromen 
bleef dit slechts over. 
Matsua Bash6 (1644-1694) samurai 
Met dank en excuses aan de proefdieren die, 
zonder k]agen, hun offer aan de wetenschap brachten. 
CONTENTS 
List of abbreviations ..................................... 7 
Chapter 1 Introduction................................... 9 
1.1 Thyroid hormone production ..................... 10 
1.2 Transport of thyroid hormones ................... 12 
1.3 Thyroid hormone metabolism .................... 12 
1.4 Thyroid hormone receptor proteins and response elements .. 26 
1.5 Scope of the thesis . . . . . . . . . . . . . . . . . . . . . . . . . .. 28 
Chapter 2 Rat liver type I iodothyronine deiodinase is not identical to 
protein disulfide isomerase . . . . . . . . . . . . . . . . . . . . . . . .. 43 
Biochem. Biophys. Res. Commun. (1989) 162, 857-868 
Chapter 3 Species differences in liver type I iodothyronine deiodinase .... 57 
Biochim. Biophys. Acta. (1992) 1121, 160-166 
Chapter 4 Impairment of the selenoenzyme type I iodothyronine 
deiodinase in C3H/He mice ... . . . . . . . . . . . . . . . . . . . .. 65 
Endocrinology (1993) 132, 357-361 
Chapter 5 Reaction of the type III deiodinase with the affinity label 
N-bromoacetyl-triiodothyronine . . . . . . . . . . . . . . . . . . . . .. 71 
FEBS letters (1993) 335, 104-108 
Chapter 6 Affinity labeling of iodothyronine deiodinases in rat tissues 
with N-bromoacetyl-iodothyronine derivatives . . . . . . . . . . . . . 77 
Submitted for publication 
Chapter 7 General discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 91 
Summary 101 
Samenvatting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 107 
Curriculum vitae 113 
Nawoord .......................................... 114 

Ac 
BrAc 
Da 
DIT 
DOC 
DTI 
EDTA 
HEPES 
HPLC 
IRD 
lOP 
Km 
MIT 
Mr 
ORD 
PTU 
rT3 
SDS-PAGE 
TO 
Tl 
T2 
T3 
T4 
TSH 
1RH 
Triac 
Tris 
Vmax 
LIST OF ABBREVIATIONS 
N-acetyl 
N-bromoacetyl 
Dalton 
3,5-diiodotyrosine 
sodium deoxycholate 
dithiothreitol 
ethylenediaminetetraacetic acid 
N -2-hydroxyethylpiperazine-N' -2-ethanesulfonic acid 
high performance liquid chromatography 
inner ring deiodination 
iopanoic acid 
Michaelis constant 
3-monoiodotyrosine 
relative molecular mass 
outer ring deiodination 
6-N-propyl-2-thiouracil 
reverse triiodothyronine (3,3',5'-triiodothyronine) 
sodium dodecyl sulphate polyacrylamide gel electrophoresis 
thyronine 
monoiodothyronine 
diiodothyronine 
3,3' ,5-triiodothyronine 
thyroxine (3,3' ,5,5'-tetraiodothyronine) 
thyroid-stimulating hormone; thyrotropin 
thyrotropin-releasing hormone 
3,3' ,5-triiodothyroacetic acid 
Tris(hydroxymethyl)aminomethane 
maximum velocity 
7 


Chapter 1 
Thyroid honnone plays an essential role in the regulation of cell growth, 
differentiation and metabolism in vertebrates. These actions are initiated by binding 
to the nuclear thyroid honnone receptor that has been identified as the translation 
product of the proto-oncogene c-erbA, the cellular counterpart of the viral oncogene 
v-erbA (1,2). Binding of thyroid honnone to its receptor changes the interaction with 
cis-acting regulatory elements, that modulate the expression of responsive target 
genes. There are several thyroid hormone receptor isofonns that exert regulation in 
an unexpected degree of complexity (3-7). Although the mechanisms of actions of 
thyroid honnone in various tissues are considered to be largely nucleus-mediated, 
several actions of this honnone are very likely extranuclear (8,9). 
1.1 THYROID HORMONE PRODUCTION 
Thyroid honnone is formed by post-translational modification of tyrosyl residues 
of the protein thyroglobulin that is synthesized in thyroid follicle cells (10,11). Iodide 
is taken up from the blood, is oxidized by H202 catalyzed by thyroid peroxidase and 
subsequently bound to tyrosyl residues of thyroglobulin, yielding monoiodotyrosyl 
(MIT) and' diiodotyrosyl (DIT) residues. Thyroid honnone is fonned from two 
iodotyrosyl residues by a subsequent coupling reaction that is also catalyzed by 
thyroid peroxidase. These steps take place at the colloidal side of the apical 
membrane, at the border of the lumen and thyroid cells. Thyroglobulin is taken up 
by the follicular cells by endocytosis and is hydrolyzed by lysosomal proteolytic 
enzymes, liberating the thyroid honnones that are subsequently released into the 
blood stream. Free MIT and DIT are deiodinated in order to reutilize the resulting 
iodide. 
The main product of the thyroid gland is 3,3',5,5'-tetraiodothyronine (thyroxine; 
T 4> In healthy humans the average production per day is 115 mnol T 4 per 70 kg 
body weight (12). T4 displays little intrinsic bioactivity and is looked upon as merely 
a prohonnone (12,13). Besides T4 the thyroid also produces 3,3' ,5-triiodothyronine 
(T 3), the main bioactive thyroid honnone. However, thyroidal synthesis accounts for 
ouly less than 20 % of total daily T 3 production, as most T 3 is generated by 
peripheral deiodination of T4 (14,15; Fig. 1). Thyroidal secretion has no significant 
contribution to the levels of diiodothyronines in the circulation (16,17). 
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Figure L Sequential deiodination of thyroxine (T4) 
Thyroid action is stimulated by thyrotropin or thyroid-stimulating hormone (TSH), 
a glycoprotein secreted by the thyrotropic cells of the anterior pituitary gland, TSH 
binds to specific receptors on the thyroid plasma membrane, thereby stimulating 
adenylate cyclase and under certain conditions phospholipase C, which results in an 
increase of intracellular cyclic AMP and activation of the phosphatidylinositol 
pathway respectively (18), This eventually results in an increased protein synthesis 
in the thyroid (19). TSH secretion is inhibited by thyroid hormones (20-22), 
dopamine (23), glucocorticoids and somatostatin (24), whereas it is stimulated by 
thyrotropin-releasing hormone (TRH), a tripeptide synthesized in the medial 
parvocellular part of the paraventricular nucleus in the hypothalamus (25). 
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1.2 TRANSPORT OF THYROID HORMONES 
Iodothyronines in the circulation are bound almost completely to plasma transport 
proteins. These are thyroxine-binding globulin (TBG), thyroxine-binding prealbumin 
(TBPA) or transthyretin (TTR), and albumin, that carry approximately 75, 15, and 
10 % of plasma T4 respectively. T3 is distributed in a more variable way over the 
transport proteins: 38-80 % bound to TBG, 9-27 % bound to TBPA, and 11-35 % 
bound to albumin (26-29). The normal serum free T4 (FT4) and FT3 levels comprise 
only about 0.02 and 0.2 % of total T4 and total T3 levels, respectively. Of the 
iodothyronine plasma transport proteins TBPA is thought to be essential for thyroid 
hormone supply to tissues (30,31). TBG levels in species such as rat, dog and sheep 
are low, making TBPA the main plasma transporter for iodothyronines. 
Because of the hydrophobic nature of iodothyronines it was assumed that these 
molecules enter the cell by passive diffusion (32). However, during the past 15 years 
evidence has accumnlated that cellular uptake of thyroid hormone is an active, 
saturable and energy-dependent process (33-37). Furthermore, it has been 
demonstrated that T4 and T3 are transported into the cell by different carrier systems 
(38,39), although they are competitive inhibitors for each others uptake. Evidence 
was found that also the transport of T 3 from cytoplasm into the nucleus is mediated 
by a stereospecific, energy-dependent transport system (40,41). 1bis would indicate 
the existence of additional means of controlling the iodothyronine concentration at 
the receptor. 
1.3 THYROID HORMONE METABOLISM 
Extrathyroidal metabolism of iodothyronines is one of the major processes 
regnlating the bioavailability of T3 (14). Removal of iodide from the outer ring of 
T4 by enzymatic deiodination will increase the level of T3, whereas its level can be 
reduced by different routes of metabolism. These routes, which will be discussed 
below, are not followed in a mutually exclusive way, but are interconnected in a 
complex manner (Fig. 2). 
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Figure 2. Metabolism of thyroxine 
1.3.1 Deiodination 
The quantitatively and qualitatively most important way of thyroid hormone 
metabolism is enzymatic deiodination. Until now three different types of deiodinases 
have been identified. These enzymes not only differ in characteristics, but also in 
their tissue distribution. Furthermore, the activity of the three deiodinases is 
regulated in a different manner by thyroid status, providing optimal intracellnlar T 3 
levels in critical tissues such as the central nervous system (14,42-44). 
Type I iodothyronine deiodinase (ID-I) is responsible for the largest part of T3 
supply to peripheral tissues, by catalyzing outer ring deiodination (ORD) ofT4' ID-I 
activity responds positively to thyroid status, being low in hypothyroidism and 
elevated in hyperthyroidism. The enzyme is capable of both inner ring deiodination 
(IRD) and ORD, and is mainly localized in liver, kidney and thyroid (14). ID-I is 
a very hydrophobic transmembrane protein, being present in liver microsomes in a 
concentration of approximately 0.01 % of total protein. In liver it is located in the 
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endoplasmic reticulum (45,46), whereas in kidney it is associated with the plasma 
membrane (47). In both organs the active site probably faces the cytoplasm. The 
enzyme requires a cytosolic cofactor of which the identity has not been resolved yet. 
ID-I in the microsomal fraction is strongly stimulated by low molecular weight thiols 
such as dithiothreitol (DTT) or reduced glutathione (GSH). Although GSH is a 
relatively weak stimulator, it is a possible candidate for the biological cofactor (48). 
ID-I can be solubilized by a number of detergents, but only few of them are able 
to keep the enzyme in an active form in the absence of membrane lipids. Sterie 
exclusion chromatography of cholate or deoxycholate (DOC) extracts of liver or 
kidney microsomes suggested a molecular mass for ID-I of ""50-60 kDa (49,50). 
When rat liver microsomes were solubilized with non-iouic detergents, a pI value of 
",,6.5 for ID-I was found in iso-electric focussing. However, upon delipidation this 
pI value shifted to ""9.3, indicating that ID-I is a basic protein (51). 
The inactive metabolite 3,3',5'-triiodothyrouine (reverse T3, rT3) is clearly the 
preferred substrate of ID-I with a V max that is at least 500-fold higher than that of 
T4' Modifications of the thyrouine structure resulting in a higher net negative charge 
of the molecule increase deiodination by ID-I. It is possible that this is caused by an 
increased affiuity for positively charged groups on the basic protein. For T4 itself 
IRD and ORD account for almost equal fractions of its metabolism. However, 
suIfation of the 4'-hydroxyl group dramatically increases the IRD of T4 but 
completely blocks its ORD, resuIting in the irreversible elimination of T4' 
The use of N-bromoacetyl (BrAc) derivatives of iodothyrouines as covalent 
affiuity-labeIs has greatly advanced the identification of ID-I. First, it was found that 
ID-I in liver is rapidly and irreversibly inactivated by minute quantities of BrAcT3 
and that this inactivation could be prevented by the presence of high concentrations 
of ID-I substrates (52). Using BrAc[125I]T3 or BrAc[125I]T4 as affiuity-labels for 
liver or kidney microsomes followed by SDS-PAGE analysis of labeled proteins, two 
major labeled protein bands were identified with relative molecular mass (Mr) of 27 
and 56 kDa. The latter represents protein disulfide isomerase (PDI) which is a major 
constituent of the lumen of the endoplasmic reticulum, where it assures the proper 
folding of newly synthesized secretory proteins by catalyzing disulfide-bond 
isomerization (53,54). It has been suggested that ID-I and PDI were one and the 
same protein (55-58) but subsequently the 27 kDa BrAcT 3-labeled protein was 
clearly identified as ID-I (59-61). As this Mr is only about half of the earlier 
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estimates for the molecular mass of ID-I of "'50-60 kDa, it is likely that the enzyme 
is a dimer, perhaps a homo-dimer. 
After it had been shown that Xenopus laevis oocytes were able to translate ID-I 
mRNA into active protein (62,63), this expression system was used to isolate the 
complete cDNA encoding rat liver ID-I (64). From this cDNA and from the DNA 
sequence of the human enzyme. (65), it was deduced that in both species ID-I is a 
selenoenzyme containing the rare amino acid selenocysteine (SeC). This amino acid 
is an extra amino acid encoded by the genetic code and therefore is inserted in the 
enzyme cotranslationally. SeC is carried by a specific tRNA complementary to the 
UGA codon that normally functions as a translation stop codon (66). There are 
strong indications that the secondary and tertiary structure of the translated mRNA 
is essential for the proper cotranslational insertion of SeC. For ID-I it was shown 
that sequences in the 3' untranslated region of the ID-I mRNA are essential for the 
recognition of UGA as a SeC codon (67). 
Selenium was first connected to thyroid hormone metabolism by the finding that 
Se deficiency in rats led to a decrease in the serum level of T 3 together with an 
increased serum T4 (68,69). The amount of ID-I in liver and kidney of rats was 
found to be strongly related to the Se status, being markedly decreased in Se-
deficient animals (68-71). Labeling studies with radioactive 75Se intravenously 
administered to Se-deficient rats identified a labeled 27 kDa liver protein (72). By 
using peptide mapping and quantitation of both the 75Se and BrAc[125I]T4 labeled 
27 kDa proteins, it was shown that they were identical (73), providing the ultimate 
evidence that the 27 kDa protein represents ID-I. 
A two-step model has been proposed for the reaction mechanism of deiodination 
catalyzed by ID-I (Fig. 3). In the first step an iodonium (1+) ion is transferred from 
the iodothyronine to an acceptor group in ID-I, resulting in the formation of an 
oxidized enzyme-intermediate. In the second step this enzyme-intermediate is reduced 
by a cofactor, regenerating ID-I and yielding oxidized cofactor and iodide. Initially, 
it was thought that the iodonium-acceptor group was a protein sulfhydryl (SH) group, 
converted into a sulfonyl iodide in the first step of the reaction (74,75). This 
assumption was supported by the finding that 6-N-propyl-2-thiouracil (PTU) inhibits 
ID-I in a manner competitive with cofactor (DTI) but uncompetitive with substrate 
(74,76). It had previously been shown that thiouracil is particularly reactive towards 
protein sulfonyl iodides, yielding mixed disulfides (77). However, since ID-I is a 
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selenoenzyme (64) it is very likely that the selenocysteine residue is the actual 
catalytic center, alternating between the selenol (SeH) and the selenenyl iodide (E-
Sel) forms during enzymatic activity. This is supported by the finding that, when 
using site-directed mutagenesis to replace selenium by sulfur (SeC -> Cys), this leads 
to a strong decrease in the catalytic efficiency of ID-I (78,79). Besides SeC also 
histidine residues have been shown to be essential for substrate binding and function 
of ID-I (80,81). 
T~3 HN 0 
E-SeH E-Sel PTU~ E-Se-S~ >-< -r N 
DTTox 
+1-
DTT
red 
Figure 3. Mechanism of type I iodothyronine deiodinase 
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The type II iodothyronine deiodinase (ID-II) is mainly responsible for the supply 
of thyroid hormone to the central nervous system by local conversion of T4 to T 3 
(82). ID-II is found in the central nervous system, pituitary and brown adipose tissue 
(14,15). Unlike ID-I the activity of the type II enzyme is markedly increased in 
hypothyroidism and decreased in hyperthyroidism (43). Thus ID-II can make a 
significant contribution to plasma T3 levels in hypothyroid sUbjects. In cultures of 
rat brain astrocytes it was found that ID-II can be induced> 10-fold by agents that 
influence cellular differentiation, such as growth factors, cAMP derivatives or 
phorbol esters (83-86). 
ID-II catalyzes only ORD of rT3 and T4 with the latter displaying the highest 
V max/I<",. The Km values for both substrates are in the nM range and, therefore, 
ID-II may display significant substrate occupancy under physiological conditions. 
Like ID-I, the enzyme is stimulated by small thiol compounds such as DTT (14,15). 
Although it has been suggested that ID-II activity can be inhibited by PTU under 
special circumstances (87), the enzyme is generally considered to be insensitive to 
PTU. Iodoacetate can inhibit enzyme activity, suggesting an essential thiol group to 
be located in the active center domain (88). 
In brain cells ID-II was shown to be an integral membrane protein (83) that can be 
selectively labeled with BrAcT4 (89). High resolution SDS-PAGE analysis of 
BrAc[ 125I]T4 labeled ID-II revealed a Mr of 29 kDa, slightly higher than the Mr 
of the type I enzyme. Employing Endo-F/peptide N-glycosidase F hydrolysis it was 
shown that apparently neither ID-I nor ID-II is glycosylated. Peptide mapping and 
cyanogen bromide fragmentation further demonstrated that the labeled ID-I and ID-II 
proteins are different. When ID-II was labeled with BrAc[125I]T4 fOllowed by 
subsequent solubilization with tauro-deoxycholate and analysis by sucrose density 
centrifugation, the enzyme was shown to have a molecular mass of 199 kDa, 
indicating a multimeric composition (90). 
The activity of ID-II in cultures of astroglial cells is not decreased by Se-
deficiency, indicating that the enzyme does not contain SeC (91). The finding that 
ID-II levels are decreased in Se-deficient rats is no prove for ID-II being a 
selenoenzyme, as T 4 levels are increased in Se-deficiency and this leads to down 
regulation of ID-II activity (92). However, increased ID-II activity resulting from 
hypothyroidism caused by iodine defiCiency is not reversed by additional Se-
deficiency in rats, indicating that ID-II is not a selenoenzyme (71). Gold thioglucose 
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is a potent inhibitor of type I deiodinase. However, when the SeC residue in the 
enzyme is replaced by Cys this leads to a 500-fold decreased sensitivity for 
inactivation by this substance. As ID-II is 100- to 1000-fold more resistant to gold 
thioglucose compared to the type I enzyme, this confirms the absence of SeC in the 
active site (93). 
In astrocytes the organization of the cytoskeleton is changed by T4 through an 
effect on actin polymerization. This modulates the turn-over of lD-lI in a direct 
manner. When T4 is absent almost all ID-ll is associated with the plasma membrane 
of the astrocyte. After addition of T 4, the increased polymerization of actin is 
associated with binding of the deiodinase to actin filaments. This promotes rapid 
translocation of the enzyme to an internal membrane compartment, leading to a 
decrease in ID-II activity (94). Therefore, the increased ID-ll activity found in 
astrocyte cultures grown in the absence of thyroid hormones is not caused by an 
increase in the rate of enzyme synthesis, but is the result of a decrease in enzyme 
degradation. This is supported by the failure of T4 to induce ID-ll inactivation in 
astrocyte cultures treated with agents that prevent actin polymerization, such as 
cytochalasins (95,96). 
The type ill iodothyronine deiodinase (ID-III) catalyzes only IRD and is considered 
an important enzyme for the inactivation of thyroid hormone, as it converts T4 to 
rT3 and T3 to 3,3'-T2 (14,15). ID-ill is predominantly present in brain (97-102) and 
placenta (103-108). In rats, the enzyme has also been detected in retina (109), skin 
(110,111), fetal intestine and fetal skeletal muscle (111,112). In chicken ID-III 
activity was found in embryonic heart cells (113) and liver (114-116). Furthermore, 
the enzyme was found in certain types of human brain tumors (117). In all these 
tissues ID-ill activity is associated with the microsomal fraction, similar 10 ID-l and 
ID-ll. Furthermore, it was found that ID-ill is inactivated by delipidation (118). ID-
ill is considered an onco-fetal protein as its ontogeny is clearly connected to 
embryonic development (116), its activity being generally higher in fetal than in 
adult tissues (100,101,119-121), whereas high activities of the enzyme are found in 
the human colon carcinoma Caco-2 cell line (122) and the monkey hepatocarcinoma 
NCLP-6E cell line (123-126). The high ID-ill activities in embryonic tissues and 
placenta indicate that this deiodinase plays a role in the protection of differentiating 
tissues against excess thyroid hormone during crucial periods. 
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In the central nervous system of the rat high ID-III activities are found in the 
cerebral cortex, whereas relatively low activities are measured in cerebellum, brain 
stem and spinal cord (97,100,101,119,120,127). Using tissue cultures originating 
from fetal or neonatal rat brain, it has been established that astroglial cells contain 
highest levels of ID-III, whereas oligodendrocytes display lowest enzyme activity 
(102,128). However, growth arrest of glial cell induced by cytotoxic drugs does not 
diminish ID-III activity, suggesting that the enzyme is also present in neurons (129). 
In humans, the enzyme is found in the fetal membranes (121), but much higher 
activities can be detected in placental trophoblasts (124,125). 
Brain ID-III activity is regulated by thyroid status in a manner similar to the type 
I enzyme, as it is increased in hyperthyroidism and decreased in hypothyroidism. 
This is supported by the reported induction of ID-III activity by thyroid hormones 
in astroglial cell cultures (130). However, these changes in enzyme levels are 
relatively small (97,101). Using cultures of hepatocarcinoma cells it was found that 
ID-III activity is correlated with the cell cycle, as enzyme activity is high in late G 1 
phase and low in the late S or G2 phase (125). In cultures of rat brain astroglial cells 
it was found that ID-III activity can be strongly induced by phorbol esters and both 
basic and acidic fibroblast growth factor. Epidermal growth factor, platelet-derived 
growth factor, and 8-bromo-cyclic AMP were poor inducers of ID-III activity (131). 
The best substrate of ID-III is T3 with a Km value about 10-fold lower than that 
for T4, although V max values are comparable. Deiodination of iodothyronines by 
ID-III is inhibited in a competitive manner by alternative substrates such as T4, T3, 
3,3'-T2, 3,5-T2 but not by very high concentrations (up to 1,uM) of the non-
substrate rT3 (97,101,116,124,131,132). Like ID-I and ID-II, ID-III is stimulated 
by small thiol compounds such as DTT, but much higher concentrations of this 
compound are needed to reach maximal enzyme activity. Sequential type reaction 
kinetics with formation of a ternary enzyme-cofactor-substrate complex was 
suggested by analysis of deiodination rate versus substrate concentration at fixed 
DTT concentrations (133). However, as these experiments were carried out under 
conditions uncertain to be suitable for this kind of analysis, they should be 
interpreted with care. ID-III activity is inhibited by iodoacetate concentrations above 
10 ,uM. Inhibition of ID-III by PTU could only be detected when high ("'= 0.1 mM) 
PTU concentrations were combined with low (:;; 1 mM) DTT concentrations (132). 
ID-III activity in rat brain, rat placenta and embryonic chicken liver is rapidly and 
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irreversible inhibited by BrAcT3 with a Kj comparable to'-the Km of T3' This is 
quite different from the inactivation of the type I enzyme by BrAcT 3, which is half-
maximal at a concentration much lower than the Km for T 3 or even the preferred 
substrate rT3' Upon reaction of rat brain and placenta microsomes with 
BrAc[125I]T3' a 32 kDa protein (P32) was prominently labeled, However, p32 was 
also extensively labeled in microsomes of rat spleen and fetal liver that both have no 
ID-III activity, Furthermore, labeling of p32 could not be dimiuished by very high 
(100 I'M) concentrations of inhibitors or substrate analogs of ID-III, some of which 
completely inhibit ID-III activity at a concentration 100-fold 10weL In embryonic 
chicken liver microsomes no p32 or another protein possibly related to ID-III could 
be identified by BrAc[125I]T3 affinity labeling, Therefore, it is unlikely that p32 
represents ID-IIIor a subunit thereof (134), This conclusion is in contrast with other 
suggestions based on similar results (135), 
Se-deficiency leads to a weak but repeatedly confirmed decrease of rat brain ID-III 
activity, although enzyme levels in placenta are unaffected, It remains to be resolved 
whether this indicates a specific Se dependence of the synthesis of ID-III or is caused 
by the multilevel change in thyroid hormone metabolism accompanying Se-deficiency 
(71), The difference between ID-I and ID-III in susceptibility to inactivation by 
BrAcT3 suggests that ID-III is not a selenoenzyme, Recently the cDNA of a tadpole 
protein displaying characteristics of ID-III has been cloned and sequenced, From this 
cDNA sequence it was deduced that the gene encodes a SeC-containing protein and 
displays a high degree of homology with the ID-I cDNA, in particular the region 
surrounding the SeC residue (136), However, until now no inner ring deiodinase 
displaying type I characteristics has been found in tadpole (137,138), Therefore, 
although this cDNA encodes a low Km deiodinase with inner ring specificity that is 
not inhibited by 1 mM PTU, it remains to be determined whether this enzyme 
represents the evolutionary divergent equivalent of ID-I or ID-IIL 
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1.3.2 Conjugation 
Conjugation is a general metabolic reaction that facilitates the excretion of a variety 
of hydrophobic endogenous and exogenous substances in bile and urine. This is 
achieved by covalent coupling of the hydrophobic substances with a hydrophilic 
molecule, yielding a more water-soluble product (139,140). For thyroid hormones 
conjugation represents, in importance, the second metabolic route that in most cases 
involves glucuronidation or sulfation of the phenolic hydroxyl group (Fig. 4). 
h h NH+ 
HO\d_\ 00-\ CH 2-6H:COO-
1 
-OoOC 0 h h NH+ 
HO o\d_\ 00-\ CH 2-6H:COO-
OH OH 1 
-0 S -0 'I \ 0 / \ CH - 6H: COO-01 01 NH+ 3 _ __ 2 
1 
Figure 4. Structures of T3 and derivatives 
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Glucuronidation represents one of the major routes of detoxification of many 
compounds in mammals. It is catalyzed by a group of homologous enzymes that use 
uridine diphosphate (UDP)-glucuronic acid as a cofactor. This cofactor is generated 
by reaction of uridine triphosphate (UTP) with ubiquitous glucose i-phosphate 
yielding UDP-glucose, followed by oxidation of this substance. The enzymes 
21 
Chapter 1 
catalyzing glucuronidation are named UDP-glucuronyltransferases (UGTs) and are 
predominantly present in liver but also in kidney, intestine and other tissues. UGTs 
were shown to be transmembrane proteins located in the endoplasmic reticulum, with 
their catalytic center oriented towards the lumen of this cell organelle (141). 
Using clofibrate and 3-methyJcholanthrene that induce bilirubin UGT and phenol 
UGT, respectively, it was shown that T4 and rT3 are glucuronidated by these 
enzymes (142-144). This was confirmed by studies using Gunn rats that have a 
defect in the gene coding for multiple phenol and bilirubin UGT isoenzymes and 
accordingly show impaired glucuronidation of T4 and rT3 (145). Alternatively, T3 
is glucuronidated by androsterone UGT that is different from phenol and bilirubin 
UGT and is encoded by a different gene. This is confirmed by the observation that 
Wistar LA, Fischer and WAG rats, that all have a defect in the androsterone UGT, 
display impaired T3 glucuronidation (142,143,146). 
After T4' rT3 and T3 glucuronides are produced in the liver, these substances are 
excreted in bile and subsequently hydrolysed by fi-glucuronidases produced by the 
intestinal microflora (147). This is ·supported by the observation that intravenous 
injection of radioactive T3 glucuronide ([125I]T3G) in intestine-decontaminated rats 
results in fecal excretion of radioactivity almost exclusively as [125I]T3G, whereas 
in control rats radioactivity is excreted in feces largely as [125I]T3 (148). The 
liberated iodothyronine can be reabsorbed in the circulation resulting in an 
enterohepatic cycle for thyroid hormone (149). Therefore, glucuronidation does not 
necessarily result in complete loss of thyroid hormone from the organism. The 
magnitude of the enterohepatic cycle has not been elucidated but seems to be higher 
in rat compared to man (150). 
Sulfation of thyroid hormones is catalyzed by phenol sulfotransferases (PSTs) that 
are located in the soluble fraction of particularly liver, kidney, small intestine, brain 
and platelets (139). PSTs form a family of homologous enzymes and are responsible 
for the sulfation of various phenols. All sulfotransferases use the same universal 
sulfate donor, 3'-phosphoadenosine-5'-phosphosulfate (PAPS) that is generated from 
inorganic sulfate and two ATP molecules (139,151). 
In rat liver iodothyronines are substrates for different types of PSTs, with the 
efficiency of suifation inversely correlated to the number of iodine atoms in the 
iodothyronine (152). Under normal conditions urinary excretion of sulfated 
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iodothyronines is negligible and only small amounts are excreted in the bile (153). 
However, if type I deiodinase activity is inhibited, for instance by administration of 
PTU, this results in increased levels of sulfated thyroid hormone in the circnlation 
and in the bile (154). Under these exceptional circumstances an enterohepatic cycle 
exists that is comparable to the one for g1ucuronidated iodothyronines, since 
snlfatases produced by certain strains of anaerobic intestinal bacteria of human and 
rat are able to hydrolyze all sulfated iodothyronines (155). 
Sulfation resnlts in a 40-200 times higher IRD by ill-I of T4 and T3, but 
completely blocks the ORD of T4 (156). For both iodothyronines snlfation results 
in a significant decrease of Km and a dramatic increase of V max values, resulting 
in rapid clearance from the circulation. Therefore, this conjugation reaction seems 
to induce the irreversible elimination of thyroid hormone, although, meanwhile it 
allows for reutilization of iodide for thyroidal hormone synthesis (157). In rats that 
were treated with the ill-I inhibitor PTU, a 4-fold increase of plasma T3S levels was 
observed (158) paralleled by a higher excretion in the bile (159). Furthermore, the 
clearance of injected T 3S was largely inhibited in these animals, also indicating the 
accumulation of the intermediate T3S in the circnlation upon inactivation of ill-I 
(158,160). These data show that deiodination is preceded by sulfation in a significant 
part of T3 metabolism in the rat (158). PTU treatment of rats resulted in as-fold 
increase of biliary excretion of T4S, demonstrating that also T4 is snlfated 
significantly in rats in vivo (161). 
Synthetic N-sulfonated iodothyronines, that have a sulfonated aminogroup of the 
alanine side chain, are deiodinated by ill-I with 4 to 17-fold higher efficiency. This 
mainly seems to result from lower Km values of ill-I for N-sulfonated thyroid 
hormones compared to native hormones. Opposed to the blocked ORD of naturally 
occurring 4'-O-snlfonated T4 it was shown that N-snlfonated T4 can be degraded by 
both IRD and ORD, indicating the importance of the site of sulfalion for efficient 
inactivation of T4 (162). 
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1.3.3 Oxidative deamination 
Conversion of the alanine side chain of thyroid hormones to the acetic acid 
derivative plays a minor but distinctive role in the metabolism of iodothyronines 
under normal conditions. Oxidative deamination of thyroid hormone was 
demonstrated in homogenates of liver, kidney and brain (13,163-166). Using 
sonicated rat kidney mitochondria, the reaction sequence of this metabolic route was 
elucidated for various iodothyronines (166). In a first step the alanine side chain is 
converted to successively a pyruvic acid and an acetaldehyde intermediate that is 
processed to the final acetic acid derivative (Fig. S). 
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In healthy humans only 2 percent of total T4 is metabolized by oxidative 
deamination resulting in the formation of3,3' ,S,S'-tetraiodothyroacetic acid, with the 
trivial name tetrac (TA4)' Furthermore, about 14 percent of T3 turnover in man 
follows this route yielding 3,3' ,S-triiodothyroacetic acid, with the trivial name triac 
(TA3)' indicating the physiological Significance of oxidative deamination (13). 
Although triac binds more tightly to the nuclear receptor protein than native T 3, it 
displays only about one tenth of the thyromimetic activity of this iodothyronine (167-
169). In the circnlation TA4 and TA3 bind more firmly to the carrier protein TEPA 
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compared with T4 and T3, whereas their relative affinity for TBG is diminished 
(27,170). 
Like their parent iodothyronines, the acetic acid analogues can be conjugated by 
glucuronidation or sulfation. In rats, the lesser iodinated derivatives such as 3,3'-
diiodothyroacetic acid are preferentially sulfated, TA3 is conjugated in both ways, 
whereas reverse TA3 and TA4 are predominantly glucuronidated (171-173). In 
human liver, TA3 and TA4 are also rapidly glucuronidated. However, in humans 
this involves the carboxyl group, yielding an ester derivative, whereas in rats 
glucuronidation involves the phenolic group, yielding an ether derivative (174). 
Sulfated TA3 (TA3S) is the best known substrate for inner ring deiodination by the 
type I deiodinase, as a result of its very high affinity for this enzyme (175,176). 
Significantly increased levels of TA3S have been found in the circulation of 
hypothyroid rats, and in rats treated with PTU that iuJtibits ID-I activity. PTU 
treatment also results in an increased biliary excretion of TA3S in rats 
(172,176,177). These observations indicate that, like T3, at least part of TA3 is 
normally degraded by successive sulfation and deiodination in rat. However, unlike 
T 3, sulfation does not appear to be an obligatory step in TA3 metabolism as it is 
efficiently cleared from the circulation by glucuronidation upon iuJtibition of both 
sulfation and deiodination (176). PTU treatment of rats causes a marked 
accumulation of the sulfate conjugate of 3,3'-TA2 in the circulation, also reflecting 
reduced deiodinative clearance (178). 
1.3.4 Ether link cleavage 
In healthy humans, ether link cleavage (ELC) probably represents the least 
important metabolic route for thyroid hormones (13,179,180), although it may be of 
more significance in rats (181,182). However, in phagocytosing human leucocytes 
ELC comprises the major route for thyroid hormone breakdown. ELC is associated 
with the "respiratory burst" that leads to generation of superoxide (Oi) and 
hydrogen peroxide (H202l, that can cause cleavage of the ether bridge between the 
two ring structures in the iodothyronine molecule. Therefore, the role of ELC may 
become more important in disease states accompanied by severe leucocytosis. In 
unstimulated leucocytes ELC is latent (182). 
25 
Chapter 1 
1.4 THYROID HORMONE RECEPTORS AND RESPONSE ELEMENTS 
Thyroid hormone effects at the genomic level are mediated via the nuclear thyroid 
hormone receptor (TR) that binds T3 with high affinity and specificity (3,183,184). 
When the TR was cloned, analysis of the coding sequence showed it to be a member 
of a large family of gene-regulating receptor proteins. All these receptors possess a 
domain, required for binding to their target genes, which contain two highly 
conserved clusters of cysteine residues thought to chelate zinc, forming so called 
zinc-fingers. Next to this DNA-binding domain the TR contains a ligand-binding 
domain that also plays a major role in receptor dimerisation and a hinge region that 
possibly also is involved with the localization in the nucleus (185). 
Sequence comparison of c-erbA cDNAs Originating from human placenta (1) and 
chicken embryo (2) revealed that they were derived from different genes nowadays 
designated TRa and TR,6. Both genes have been found in the genome of all 
vertebrate species examined until now. In the human genome these genes are located 
on chromosomes 17 and 3, respectively (185). Further diversity in thyroid hormone 
receptor proteins is generated by alternative splicing of the primary transcript of the 
TRa gene. This yields two different mRNAs that result in translation to al and a2 
proteins (186-188). The amino acid sequence of these proteins are identical up to 
residue 370, but differ C-terminal of this residue. As the thyroid hormone-binding 
domain is situated in the C-terminus this results in a marked difference: TRal is a 
fully functional receptor, whereas the a2 protein is defective in binding of T3 and 
cannot by itself mediate T3 responsiveness. However, it can inhibit T3 responses 
through other thyroid hormone receptors by yet unknown mechanisms (189,190). 
The TR,6 gene also encodes two different receptor proteins named TR,61 and 
TR,62. However, for the TR,6 gene diversity is not induced by alternative splicing 
of RNA but by use of alternative translation initiation sites. This results in the 
synthesis of two completely functional thyroid hormone receptors, that have identical 
amino acid sequences for the three functional domains but posses different N-
terminal regions (191). The various TR isoforms are expressed in different levels in 
a tissue-specific pattern, resulting in ratios of isoforms that vary from tissue to tissue 
(192,193). Furthermore, the levels of TR mRNAs are possibly affected in an 
isoform-specific manner by hormones and other regulatory factors (194,195). These 
findings could thus explain, at least part of, the observed differential tissue 
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responsiveness to thyroid hormone. 
Thyroid hormone resistance is a collection of syndromes characterized by reduced 
responses of target tissues to thyroid hormone. Affected individuals have increased 
thyroid hormone plasma levels combined with a normal or elevated TSH 
concentration, but usually require no treatment as they are cliuically euthyroid. In 
most cases studied, this syndrome results from mutations in the TRp-gene resulting 
in an amino acid substitution in the thyroid hormone-binding domain of the receptor, 
or even in the partial or complete deletion of this domain. Thyroid hormone 
resistance is inherited in a dominant negative fashion, as the mutant receptors inhibit 
the function of unaffected p-receptors (in heterozygotes) and normal a-receptors. 
This may result from competition for specific regulatory DNA elements and/or 
formation of inactive dimers (196-199). 
Current models for thyroid hormone action suggest that T3, the iodothyronine 
displaying the most potent bioactivity, enters the cell and migrates to the nucleus 
where it binds to its receptor. The resulting T3-receptor complex regulates the 
activity of target genes by interacting with. thyroid hormone response elements 
(TREs) situated in the regulatory sequences of these genes. Using molecular biology 
techniques, TREs have been identified and sequenced in several genes. All these 
TREs seem to contain two copies of a more or less conserved general motive, or 
consensus sequence that is referred to as a half-site. Like steroid hormone receptors, 
the thyroid hormone receptors appear to bind as dimers and to interact with two half-
sites. The functional specificity of TREs may be exerted by the orientation of the two 
copies of the consensus sequence and the number of nucleotides separating them 
(200-202). 
Binding of a thyroid hormone receptor dimer to a TRE can result in either positive 
or negative regulation of the transcriptional activity of the gene. In the latter case the 
TRE is predominantly situated near the TATA box, a DNA motive situated close to 
the transcription start site of most genes (203-205). Therefore, a steric mechauism 
was proposed for this down regulation of gene activity. However, negative TREs 
have also been found more upstream of the TATA box, suggesting the TRE 
sequence to be more important than its location (200). Another model for the 
regulation of genes emerges from the finding that thyroid hormone decreases binding 
of TR homo-dimers to specific TREs (206). In this model, unliganded, DNA-bound 
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TRs cause a diminished gene activity that is reversed by T 3-binding to the receptor 
and its subsequent release from the TRE. 
1.5 SCOPE OF THE THESIS 
The studies described in this thesis were undertaken to gain more knowledge in the 
genetic and molecular mechanisms involved in the regulation of thyroid hormone 
bioactivity. The investigations were focussed on the characterization of thyroid 
hormone deiodinating enzymes, especially ID-I and later ID-Ill. 
Chapter 2 descnbes a study performed to identify the substrate-binding subunit of 
rat liver microsomal ID-I, using affinity-labeling with BrAcT3. Furthermore, it 
aimed to test the hypothesis in previous literature that ID-I was identical to protein 
disulfide isomerase. Identification of ID-I is done by inhibition of labeling of this 
protein by the presence of substrates and inhibitors of ID-I. Furthermore, 
correlations were assessed between ID-I activity and protein-labeling under widely 
varying conditions such as protease treatment and progressive elimination of 
microsomal proteins. 
In order to elucidate the genetic structure of the gene encoding ID-I, one of the 
strategies included the purification of the ID-I protein for subsequent determination 
of its amino acid sequence. As it was impossible to purify rat or human ID-I to a 
quality and quantity high enough to meet the demands for protein sequencing, 
various other species were explored as alternative sources for the purification of ID-
I. In this interspecies comparison, that is described in Chapter 3, both concentrations 
and characteristics of ID-I in liver microsomes were investigated. 
Around this time the genetic structure of rat and human ID-I cDNA was elucidated 
by others and was shown to contain the rare amino acid SeC that is inserted co-
translationally and is encoded by a TGA codon that normally signals termination of 
translation. In the interspecies comparison the laboratory mouse substrain Balb/c had 
been used as the murine representative. It was found that ID-I varied considerably 
between various substrains, and that most mice of the C3H/He substrain were almost 
devoid of liver ID-I activity, with the other mice displaying highiy variable enzyme 
levels. The studies in Chapter 4 describe the investigations undertaken to identify the 
molecular mechanisms responsible for these phenomena. ID-I activity in C3H/He 
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mice was compared with levels of ID-l mRNA in these animals. Furthermore, the 
possible role of selenium in mouse ID-l was investigated using r7SSe]-selenite 
injection of Se-deficient or control mice. 
In the multi-species comparison of ID-l a prominently labeled band with Mr of 32 
kDa was seen in pig liver microsomes. Several other observations were in agreement 
with the idea that this band might represent ID-m. In the studies reported in 
Chapter 5 the possible relation between the 32 kDa band and ID-m is investigated, 
by affinity-labeling of this protein with BrAcT 3 in the presence of substrates and 
inhibitors of ID-m. Furthermore, this possible relation is examined in microsomes 
originating from fetal rat liver and embryonic chicken liver. 
Chapter 6 further explores the possible link between ID-m and the 32 kDa protein, 
employing labeling with the non-substrate derivative BrAcrT 3 in the presence of 
substrates and inhibitors of ID-m. Prevalence of ID-m activity was compared to 
prevalence of the labeled 32 kDa band in various organs and their subfractions. 
Using peptide mapping, it was investigated if the labeled 32 kDa protein is identical 
in these organs. 
In the General Discussion (Chapter 7) the reasons for performing the studies 
described in this thesis are discussed. Furthermore, the results of these studies are 
evaluated together with related results reported by others in literature. Finally, some 
possibilities for future research are reviewed. 
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SUMMARY: This study was done to test the recent hypothesis (Boado et al. 
(1988) B1ochem. B1ophys. Res. Commun. 155, 1297-1304) that type I ioclothyro-
nine deiod1nase (In-I) is identical to protein disulfide isomerase (POI). 
Autoradiograms of rat liver microsomal proteins, labeled with N-bromoacetyl-
r125 I]tri1odochyronine (BrAc[ 12Sr]T3) and separated by 50S-PAGE, show predomi-
nantly 2 radioactive bands of Mr 27 and 56 kOa. Substrates and inhibitors of 
10-1 inhibited labeling of the 27 kOa band but not that of the 56 kOa band. 
Treatment of microsomes with trypsin abolished labeling of the 27 kOa protein 
and destroyed the activity of 10-1 but did not prevent labeling of the 56 kOa 
protein. Following treatment of microsomes at pH 8.0-9.5 or with 0.05 % deoxy-
cholate (DOC) POI content and labeling of the 56 kDa protein were strongly 
diminished but 10-1 activity and labeling of the 27 kOa protein were not 
affected. The latter decreased in parallel after treatment at pH ~ 10. Rat 
pancreas microsomes contain high amounts of POI but show no 10-1 activity. 
Reaction of these microsomes with BrAc(125IJT3 results in extenSive labeling 
of a 56 kDa protein but no labeling of a 27 kDa protein. Pure POI (Mr 56 kOa) 
was readily labeled by BrAc[125I]T3 but showed no deiodinase activity. These 
results strongly suggest that the 27 kDa band represents (a subunit of) 10-1 
while the 56 kDa band represents POI. From these and other data it is conclu-
ded that POI and 10-1 are not identical proteins. " 1999 Ac"do!l\l.c P~c"'" 1m:. 
In humans and animals, the development and metabolic function of many tis-
sues is under con~rol of thyroid hormones of which 3, 3' , 5-triiodothyronine 
(T3) is the predominant bioactive form. This control is largely exerted by the 
interaction of the T3-nuclear receptor complex with cis-acting DNA sequences 
which regulate the transcription of thyroid hormone-responsive genes. Thyroid 
hormone receptors have recently been identified as the products of the c-erbA 
proto-oncogenes (1,2). In humans and rats, most plasma T3 is derived from the 
enzymatic deiodination of thyroxine (T4), while only about 20 % of T3 is 
secreted by the thyrOid gland (3). In keeping with its low affinity for the 
nuclear thyroid hormone receptor (I), T4 possesses little intrinsic bioac-
tivity and is generally looked upon as a prohormone for T3 (3). 
Several iodothyronine-deiodinating enzymes have been identified, but the 
type I iodothyron1ne deiodinase (ID-I) of liver and kidney is most important 
Type I deiodinase is not identical to PDI 
for peripheral production of T3 (3). However. the inactive metabolite 3,3;,5;-
triiodothyronine (reverse T3, rT3) is clearly the preferred substrate of 1D-1 
(3). In liver, 1D-1 is associated with the endoplasmic reticulum. where it 
constitutes -0.01 % of total microsomal protein (4). It is a basic protein 
that in the de11pidaced state has a pI value of 9.3 (5). 
demonstrated the usefulness of N-bromoacecyl-[12SI ]T3 
specific affinity-label of this enzyme (4). 
Previous studies have 
(BrAc[12Sr ]T3) as a 
Recently. it was claimed (6) that 1D-1 is identical to protein disulfide 
isomerase (POI); this claim was based on characterization of a clone purpor-
ting co code for 1D-1 whose sequence was found (6) to be that already deter-
mined for PDt (7). PDt is a majo~ constituent of the lumen of the endoplasmic 
reticulum, where it catalyses formation of disulfide bonds in newly-synthes-
ized secretory proteins (8.9). Accordingly, it is especially abundant (1-2 % 
of total microsomal protein) in tissues with high rates of protein secretion 
such as liver and pancreas (9). PDI from several vertebrate sources has been 
established as an acidic protein with pI < 4.5 and subunit Mr of H57 kDa 
(10,11). Recent findings indicate that PDt is ~eadily labeled with BrAc[125 t ]_ 
T3 (12,13). Because of their apparent differences, the hypothesis that POI and 
ID-I are identical p~oteins is surprising. The purpose of this study was to 
test this hypothesis by analySis of the BrAc[125t ]T3 labeling of rat liver and 
pancreas microsomes and the PDt contents and tn-I activities of these frac-
tions under different conditions. The clear dissociation between the latter as 
well as the complete lack of ID-I activity of pure POI indicate that these 
enzymes represent completely different p~oteins. 
MATERIALS AND METHODS 
Materials. [3' ,5,_125I]rT3 and [3'_125I]T3 (> 780 Ci!mmol) were obtained from 
Amersham (Amersham; UK); unlabeled iodothyronines from Henning (Berlin. FRG); 
4-aminodiphenylamine diazonium sulfate, sodium deoxycholate (DOC), 3,S-di-
iodotyrosine (DIT). dithiothreitol (DTT), naphthol .AS-MX phosphate. 6-n-
propyl-2-thiouracil (PTU), soybean trypsin inhibitor and trypsin from Sigma 
(St. LouiS, MO); iopanoic acid (lOP) from Sterling Winthrop (Newcastle, UK); 
electrophoresis grade SDS-PAGE reagents from Bio-Rad (Richmond, IL); Mr mar-
kers and Sephadex LH-20 from Pharmacia (Uppsala, Sweden); Coomassie B~illiant 
Blue R-250 from Merck (Darmstadt, FRG); Tween 20 from Serva (Heidelberg, FRG); 
goat anti-rabbit IgG conjugated with alkaline phosphatase (GAR-AP) from Tago 
(Burlingame. CA). 
Preparation of microsomes. Microsomes were prepared from perfused livers of 
male Wistar rats (-200 g BW) in buffer A (10 roM Tris/HCI, pH 7.4, 3 roM EDTA 
and 3 mM DTT) as previously described (14) and stored at -70 C. Rat pancreas 
microsomes were prepared similarly without perfusion of the tissue. Protein 
content was measured with the Bio-Rad protein assay using bovine serum albumin 
as the standard~ 
Deiodinase assay. ID-1 activity was determined by incubation of the appro-
priate amount of microsomal protein for 20 min at 37 C wi~h 7S nCi [125IJrT3 
and 10 nM or 1 uM rT3 in 200 ul buffer B (0.2 M phosphate, pH 7.2, 4 mM EDTA 
and 3 roM DTT)~ The reaction was sto~ped by placing the samples on ice and 
adding 750 ul of 1 M HCI. Released 12 1- was separated from iodothyronines on 
45 
Chapter 2 
46 
Sephadex LH-20 as described before (15), and the data were corrected for 
enzymatic deiod1nation as determined in incubations without microsomes. 
calculation of ID-I activity, random labeling of the 3; and S~ positions 
[12SrJrT3 was taken into account. 
non-
For 
of 
Treatment of microsomes with DOC or hi h pH. Rat liver microsomes (7.2 mg 
protein were suspended in 10 ml 25 roM HEPES (pH 7.4), 0.25 M sucrose and 50 
mM KCl with or without 0.05 % DOC or in 0.1 M sodium carbonate (pH 8.0-11.5). 
The mixtures were kept on ice for 1 h with occasional stirring and subsequent-
ly layered on 2 ml 50 mM HEPES (pH 7.4), 0.5 M sucrose, 50 roM KCl and 2 roM 
DTT. and centrifuged for 90 min at 105,000 x g and 4 C. The resulting pellets 
were resuspended in 1 ml of buffer A and stored at -20 C. as yere the super-
natants. until further examination. 
Synthesis of BrAc[12SI]T3' The affinity-label was prepared essentially as pre-
viously published (4). The product Yas checked by HPLC, shOwing at least 80 % 
purity Yith unreacted [12SI1T3 as the main contaminant. 
Affinity-labeling. The desired amount of BrAc[12SI]T3 yas brought in an Eppen-
dorf tube and the solvent was evaporated at 42 C under a stream of nitrogen. 
To the residue yas added the desired amount of microsomal protein in 60 ul 
buffer A. and the mixture yas vortexed for 30 s. After further incubation for 
10 min at 37 C. 30 ul of SDS-sample buffer containing S % fi-mercaptoethanol 
yas added to stop the labeling, and proteins yere separated by SDS-PAGE in a 
10 % gel (6). Gels Yere st-ained with 0.25 % Coomassie Briliant Blue R-2S0 in 
SO % methanol/l0 % acetic acid and destained with S % methanol/7.5 % acetic 
acid, both at 60 C. Gels were dried under vacuum and autoradiographed at -70 C 
with Kodak T-MAT G film. After autoradiography, lanes were excised from the 
gel and cut into 1 mm fractions, which were counted for radioactivity. 
Protein disulfide isomerase. POI was purified to homogeneity from bovine liver 
by published procedures (17). Rabbit po1yclonal antiserum was raised against 
the purified enzyme (18) and anti-PDI antibodies were immuno-affinity-purified 
from the antiserum by adsorption onto the antigen blotted onto nitrocellulose 
paper (S.J. Murant and R.B. Freedman, in preparation). 
lmmunoblotting. Proteins were separated by SDS-PAGE and transferred to a 
nitrocellulose filter by the electroblotting method of Towbin et a1. (19). 
Blots were subsequently blocked with skimmed milk. incubated for 2 h with SOO-
fold diluted anti-bovine PDI antibodies or non-immune serum, and for 2 h with 
103-fold diluted GAR-AP with appropriate intermittent washings (PBS/O.OS % 
Tween 20). The blots were stained for alkaline phosphatase using a mixture of 
4-aminodiphenylamine diazonium sulfate and naphthol AS-MX phosphate (20). 
Reproducibility. The data shown are from representative experiments which were 
repeated 2 or 3 times Yith closely agreeing results. 
RESULTS 
Reaction of rat liver microsomes with BrAc[12SI JT3 resulted in the predomi-
nant labeling of 2 protein bands with ~ 27 and 56 kOa. Figure lA shows that 
labeling of the 27 kDa band was strongly inhibited if the reaction with BrAc-
[12SIJT3 was carried out in the presence of 10 uM rT3• Inhibition was also 
observed Yith 100 uM PTU and to a lesser extent with 10 uM lOP, whereas 
addition of 10 uM T4 , T3 • OIT or thyronine (TO) had no significant effect. 
Inhibition of labeling of the 27 kOa band by rT3 and/or PTU was accompanied by 
an increased BrAc[125I ]T3 incorporation into the 56 kDa protein. Labeling of 
the latter was only Slightly diminished by T3 and TO and was not affected by 
lOP or DIT. 
Labeling of the 27 kDa band was completely inhibited by coincubation Yith 
10 uM rT3 and 100 uM PTU. The reversibility of this inhibition was investiga-
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Effects of substrates and inhibitors of ID-I on the labeling of rat 
liver microsomal protein with BrAc[ 125r]T3. 
A: Mlcrosomes (50 US prOtein) were reacted for 10 min at 37 C with 0.5 
uC1 BrAc[125r ]T3 as described in Materials and Methods in the absence 
or presence of 10 uM tIS. T4. T3. DIT, TO. or lOP. or 100 UK PTU or 10 
UK tI3 + 100 UK PTU. After SDS-PAGE. film was exposed for 4 h. 
B: Mlcrosomes were incubated for 10 min at 37 C without ~r with 10 UK 
rT3 and/or 100 UK PTU. Subsequently. microsomes were isolated by cen-
trifugal column chromatography on Sephadex LH-20 (21), and 50 ug pro-
tein thus obtained was reacted for 5 min at 37 C with 0.5 uCi BrAc-
[125I1T3' After SDS-PAGE, film was exposed for 4 h. 
ted by preincubation of microsomes for 10 min with 10 uM rT3 or 100 uM PTU 
alone or in combination. FollOwing removal of the inhibitors on Sephadex LH-20 
using the centrifugal column chromatography method of Penefsky (21). the 
microsomes were reacted for 5 min with BrAc[125I ]T3• Figure lB shows that pre-
incubation of rat liver microsomes with rT3 or PTU alone did not affect 
labeling of the 27 kDa band. However. in combination rT3 and PTU completely 
eliminated subsequent BrAc[125I ]T3 incorporation into the 27 kDa protein. 
Again, this was accompanied by a significant increase in the labeling of the 
56 kDa band. 
The effect of trypsinization on the labeling of the 27 and 56 kDa bands was 
studied by treatment of 120 ug microsomal protein for 1 h at 37 C with 2 ug of 
the protease. Digestion was terminated by addition of excess soybean trypsin 
inhibitor. Half of the mixture was reacted for 20 min at 37 C with 0.35 uCi 
BrAc[125I ]T3• and proteins were separated by SDS-PAGE. Figure 2 shows that 
after trysinization only a faint band appears at the position of t~e 27 kDa 
protein after prolonged exposure of the film. while labeling of the 56 kDa 
protein was rather increased following trypsin treatment. 
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Effects of treatment of rat liver microsomes with trypsin on protein 
labeling with BrAc[125I]T3_ Microsomes (120 ug protein) were incubated 
for 1 h at 37 C without (-) or with (T) 2 ug trypsin. followed by addi-
tion of 6 ug soybean trypsin inhibitor. Microsomal protein (60 ug) was 
subsequently labeled for 20 min at 37 C with 0.35 uC1 BrAc[12Sr ]T3 and 
analysed by 5DS-PAGE. Film exposure was for 17 h. 
1D-I activity was determined in the remainder of the crypslnized microsomes 
in parallel with untreated controls. At a microsomal protein concentration in 
the assay of SO ug/ml, ID-I activity waS undetectable in trypsin-treated 
microsomes. whereas complete deiodination of substrate was observed in con-
trol microsomes. No effectS"'of trypsin on protein labeling or ID-I activity 
were seen if trypsin inhibitor was added to the microsomes before the protease 
(not shown). Previous work has established that, in conditions where marker 
enzymes of the cytosolic surface of microsomal membranes are extensively 
degraded by proteases, PDI is completely protected from degradation (22). 
After treatment of rat liver microsomes with carbonate buffers of increas-
ing pH, ID-I activity of the resulting membrane fractions remained constant 
over the pH-range 8.0 to 9_5 and strongly diminished at pH ~ 10. Figure 3A 
shows an autoradiogram of the labeled proteins separated by SDS-PAGE after 
reaction of these microsomal preparations with BrAc[12Sr ]T3_ The quantitative 
results of these experiments are presented in Table 1. The incorporation of 
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A: Influence of pretreatment of rat liver microsomes at pH 8.0-11.5 or 
~th 0.05 % DOC on labeling of proteins with BrAc[125I)T3_ Mictosomes 
(7.2 mg protein) were processed as described under Materlal~ and 
Methods. The resulting membrane suspensions (15 ul) ~re diluted 4-fold 
and reacted for 5 min at 37 C with 0.25 uCi BrAc[125I]T3_ After SDS-
PAGE, film was exposed for 2 h. 
B: Appearance of pnr on Western blot after pretreatment of rat liver 
microsomes at pH 8.0-11.5 or with 0.05 % DOC. After pretreatment, pro-
teins in the resulting membrane suspensions (15 ul) were diluted 4-
fold, separated by SDS-PAGE and transferred ~o a ni~rocellulose fil~er. 
PDI was visualized by rabbi~ anti-bovine PDI antibodies as described 
under Materials nnd Methods. No bands could be detected with non-immune 
serum (not shown). 49 
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TABLE 1 
Effects of pretreatment:: of rat liver microsomes at pH 8.0-11.5 on ID-I 
activity and labeling of 27 and 56 kDa proteins with ErAc(lZSrJT3 
Pretreatm,ent pH ID-1 activity 
(% rT3 -> r-) 
% ErAc[ 125r)T3 incorporation 
27 kDa 56 kDa 
8.0 34.8 58.1 12.7 
8.5 29.7 56.3 11.0 
9.0 27.4 57.8 6.3 
9.5 31.9 61.5 1.4 
10.0 21.0 49.1 1.5 
10.5 2.2 8.2 1.8 
11.0 0.2 4.4 2.0 
11.5 0.1 4.2 3.4 
Lanes were excised from the gel depicted in Fig. 3A and cut into mm 
fractions. Fractions containing the 27 and 56 kDa proteins were counted 
for radioactivity. 10_I activity was determined after 160-fold dilution 
of unfractionated samples as described under Materials and Methods. 
BrAc[125I ]T3 into the 27 kDa band closely paralleled the ID-I activity of the 
membrane fractions, shOwing a pronounced diminution only at pH ~ 10. However, 
labeling of the 56 kDa protein was much more sensitive to elevation of pH, 
being virtually undetectable after washing microsomes at pH 9.5 and higher. 
Immunoblots of carbonate buffer-treated microsomes showed a decrease of POI 
that paralleled the decreased incorporation of BrAc[125r ]T3 into the 56 kDa 
band. Figure 3B shows an example of this. 
Pretreatment of microsomes with 0.05 % DOC resulted in the complete elimi-
nation of BrAc[125r1T3 labeling of the 56 kDa protein band (Fig. 3A). This was 
paralleled by the disappearance of POI on immunoblots of DOC-treated micro-
somes (Fig. 3B). However, extraction of microsomes with 0.05 % DOC affected 
neither ID-1 activity (not shown) nor labeling of the 27 kDa protein with 
BrAc[125I ]T3 (Fig. 3A). 
Rat pancreas microsomes wer_e completely devoid of ID-I activity when tested 
at protein concentrations between 5 and 500 ug/ml. whereas rat liver micro-
somes showed 43 % deiodination at 5 ug protein/ml. Figure 4A shows that reac-
tion of rat pancreas microsomal proteins with BrAc[125I ]T3 resulted in the 
labeling of predominantly 2 protein bands with ~ 52 and 56 kDa. Both bands 
were visualized with anti-POI antibodies on Western blots (not shown). Even 
after prolonged exposure of the film, no radioactive band corresponding to a 
27 kDa protein could be detected. 
Purified bovine PDr (1 ug) was reacted with 0.2 uCi BrAc[125r ]T3• This 
resulted in a clearly labeled 56 kDa protein band (Fig. 4B). The homogenous 
POI showed no 1D-1 activity when tested at concentrations of 5 or 50 ug/ml, 
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Fig.4. A: Autoradiogram of BrAc[125IJT3-label~d rat pancreas microsomes after 
SDS-PAGE. Rat pancreas microsomes (SO ug protein) were reacted for 5 
min at 37 C with 0.5 uCi BrAc(125I]T3_ Film was exposed for 2 h. 
B: Autoradiogram of BrAc[125I]T3-1abeled bovine PDI after SDS-PAGE. pDt 
(1 ug) was reacted for 10 min at 37 C with 0.2 uC1 BrAc(12SI)T3_ Film 
was exposed for 19 h. 
while rat liver microsomes showed 40-100 % deiodiuation in parallel incuba-
tions at similar total protein concentrations. 
DISCUSSION 
The evidence that the 27 kDa protein which is labeled by reaction of rat 
liver microsomes with BrAc[12St ]T3 represents ID-I or a subunit of this enzyme 
may be summarized as follows. 
1) Labeling of the 27 kDa protein is inhibited by the preferred ID-I substrate 
rT3 and the competitive inhibitor lOP but is little affected by the poor sub-
strateS T4 and T3 or the non-substrates DIT and TO. Although PTU itself also 
inhibits BrAc[12SI ]T3 incorporation into the 27 kDa protein, its action is 
potentiated in the presence of substrate. This is especially evident in the 
experiments where preincubation of microsomes with either PTU or rT3 alone had 
no effect on the labeling of the 27 kDa protein, whereas preincubation with 
PTU plus rT3 completely eliminated subsequent labeling of this protein. These 
results are compatible with the view that the uncompetitive inhibition of ID-I 
by PTU is due to covalent binding of the inhibitor with a substrate-induced 
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oxidized form of the enzyme, probably a sulfenyl iodide intermediate (3). 
2) Labeling of the 27 kDa protein is inhibited in parallel with a decrease in 
ID-I activity following treatment of rat liver microsomes with trypsin. 
Further. neither labeling of the 27 kDa protein nor ID-I activity are affected 
by treatment of microsomes with 0.05 % DOC or with buffers of pH 8.5-9.5. 
conditions which are known to specifically release luminal proteins (22.23). 
These results are in agreement with the idea that 1D-1 1s a cytoplasm-or1en-
ted. transmembrane protein of the endoplasmic reticulum (24,25). The correla-
tion between labeling of the 27 kDa protein and ID-I activity is further 
underscored by the parallel decrease in these parameters following treatment 
of microsomes with buffers of pH ~ 10. 
3) Previous findings in our laboratory have suggested that the kinetics of ID-
I inactivation by BrAcT3 are indentical with the kinetics of BrAc[125I ]T3 
incorporation into the 27 kDa protein (4). 
4) The tissue distribution of the microsomal 27 kDa protein labeled with BrAc-
[125I1T3 or BrAc[125t ]T; appears to correspond with the occurence of ID-I 
activity. This is suggested by the high levels found in liver (ref. 4; this 
paper) and kidney (26), and the lack of ID-I activity and of the labeled 27 
kDa protein in pancreas. 
There is a clear discrepancy between the Mr of the 27 kDa protein labeled 
in rat liver and kidney microsomes with bromoacetyl-iodothyronine derivatives 
and the minimum molecular weight estimates for detergene-dispersed ID-I 
preparations, i.e. 55-60 kDa (27,28). This suggests that the 27 kDa protein 
indeed represents a subunit of the deiodinase, but it remains to be establis-
hed if ID-I is composed of identical or different subunits. 
Several lines of evidence suggest that incorporation of BrAc[125I ]T3 into 
the 56 kDa microsomal protein represents labeling of PDt; these may be summa-
rized as follows. 
1) Parallel changes were observed in the PDI content of microsomes, determined 
on Western blots, and the extent of labeling of the 56 kDa protein by BrAc-
[125IJT3' after various treatments of the microsomal preparations. Thus, 
treatment with trypsin had n~·effect on the labeling of the 56 kDa protein or 
the PDt content, as previous studies showed the protease-resistance of PDt in 
intact microsomes (22). Treatment of microsomes at pH ~ 9 or with low concen-
trations of surfactant (0.05 % DOC) released PDt from the microsomal prepara-
tions, as judged by its disappearance from Western blots of microsomal 
proteins after these treatments; labeling of the 56 kDa protein by 
[125IlT3 decreased in parallel. The behaviour of the 56 kDa reactive 
is therefore characteristic of a protein located on the luminal side 
endoplasmic reticulum membrane, such as POI (22,29). 
BrAc-
protein 
of the 
2) Labeling of the 56 kOa band is extensive in tissues with a high POI con-
Type I deiodinase is nol identical 10 PDI 
tent, i.e. liver and pancreas; we have not analysed tissues with low PDI acti-
vity. 
3) Purified PDI 1s extensively labeled with BrACr125I]T3' producing a radio-
active band that eomigrates with the labeled 56 kDa microsomal protein on SDS-
PAGE. which 1s in close agreement with the molecular weight for PDI of 56.8 
kDa (7.17). 
4) Other investigators have purified the BrAc[12Sr ]T3-1abeled 56 kDa protein. 
On the basis of monoclonal antibodies produced against this protein, they have 
isolated and sequenced eDNA clones that were found to code for PDr (12.13). 
The high susceptibility of POI to modification with alkylae1ng agents and 
its abundance in rat liver and pancreas (9) explain its extensive labeling 
~th BrAc[125I1T3 in microsomes of these tissues. A possible contributory fac-
tor in the ready labeling of PDI by BrAc[125I )T3 is the presence within the 
sequence of PDI of a domain highly homologous in sequence. to the steroid-
binding region of the mammalian oestrogen receptor (30); this domain might 
have some affinity for T3 analogues. 
The non-identity of In-I and PDI is further substantiated by the widely 
different properties reported for these enzymes. As mentioned above, PDI is 
known to be an acidic protein ~th a pI of 4.2 (10), whereas in the delipida-
ted state In-I is a basic protein of pI 9.3 (5). Moreover, in contrast to the 
abundance of PDI in liver, where it represents 1-2 % of microsomal protein 
(9), the level of In-I in rat liver microsomes amounts to only -0.01 % of 
total protein (4). It has recently been reported that In-I activity is expres-
sed in Xenopus ~ oocytes by injection of a polyadenylated rat liver RNA 
fraction of 1.5-2.0 kb, while mRNA fractions of greater size were ineffective 
(31). Since the major PDI mRNA species in rat liver is 2.8 kb in size (7). 
this observation also implies that PDI and In-I are not identical. 
The reason that Boado et alp (6) have cloned cDNA that codes for PDI in the 
course of experiments designed to elucidate the sequence of In-I must be 
sought in the nonspecific screening method they have used. This was done by an 
indirect assay of proteins produced by clones of a liver cDNA library which 
competed with ID-I in CHAPS-solubilized microsomes for binding to polyclonal 
antibodies raised against crude liver microsomal protein (32). It is known 
that solubilization of rat liver microsomes with CHAPS gives rise to the 
formation of large complexes that apart from lipid and detergent may be compo-
sed of multiple proteins (5). It may be envisaged in such a procedure. there-
fore, that antibodies which apparently bind to certain microsomal proteins 
(e.g. ID-I) are in fact specific for epitopes on other proteins (e.g. PDI) 
also present in these complexes. It is even possible that artefactual associa-
tion between ID-I and PDI in such complexes may arise from the functional 
properties of the proteins. ID-I is regularly assayed in the presence of DTT 
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as reductant, and the small dithtol-containing cyeosolic protein thioredoxin 
is - to a limited extent - capable of supporting microsomal deiod1nation (33). 
The sequence of PDI contains tvo domains which are highly homologous to thio-
redox1n (7,9), and could thus interact with the active site of ID-I. 
In conclusion, we have provided strong evidence that the hypothesis that 
PDI and 1D-1 are the same protein 1s not correct. The identity of ID-I, there-
fore, remains to be determined. 
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The type I iodothyronine deiodinase (10·0 of liver is an important enzyme for the conversion of the prohormone thyroxine (T4 ) 
to the active thyroid hormone 3,3' 's.triiodothyronine (T). Because it is an integral membrane protein of Jow abundance. 
purification of 10-1 from rat liver has proven to be difficult. We have analyzed 10-1 in liver microsomal fractions from various 
animals to reveal possible species differences and to explore alternative sources for the isolation of the enzyme. ID-I was 
characterized by enzyme assay with 3.3' .s'-triiodothyronine (rT) as the preferred substrate and by affinity-labeling with 
N_bromoacetyl_[I2SUr) (BrAc[l2SITr). Labeled ID-I subunit was identified and quantified by SOS-PAGE and autoradiography, 
The M, of ID-I in the species investigated varied between 25.7 and 29.1 kDa. Rat and dog liver microsomes h::td a markedly 
higher enzyme content than microsomes of human. mouse. rabbit. cow. pig. sheep. goat. chicken or duck liver. Rat liver 
microsomes showed the highest 10-1 activity of all species CX:l.mined. Turnover numbers for ID-I varied between 264 and 1059 
min - 1. with rabbit and goat showing the highest values. However. dog liver 10-1 displayed an exceptionally low turnover number 
of 78 min - 1. In conclusion. ID-I has similar properties in all species examined with the notable exception of dog. 
Introduction 
The th)(roid gland of healthy humans produces pre-
dominantly T4• which shows little intrinsic bioactivity 
and is therefore regarded as a prohormone. By deiodi-
nation. T4 is converted to the bioactive thyroid hor-
mone T3 or to the biologically inactive metabolite rT). 
About 80% of circulating T3 and more than 95% of 
circulating rT) are generated by peripheral deiodina-
tion of T4 • Deiodination is also an important pathway 
for the metabolism of T) and rT). yielding in both 
cases 3.3'-diiodothyronine (3,3'-T2) as the product [1]. 
The enzyme ID-l. predominantly located in liver 
and kidney, is responsible for the major part of periph-
eral T) production [1]. In human and rat liver. ID-I is 
associated with the endoplasmic reticulum and displays 
both 5- and 5'-deiodinase activities [IJ. The enzyme 
shows preference for rT) as substrate and is specifically 
inhibited by 6-propyl-2-thiouracil (PTU) [1]. Affinity~ 
Abbreviations: 1001, type I iodothyronine deiodinase: T4 • prohOf-
mone thyroxin: T~, 3,3',5·triiodothyronine: rTJ' reverse 3,3',5'·tri-
iodothyronine: Pl11. 6,propyl·2·thiouracil: PDI, protein disulfide 
isomerase; BrAc(IZIlTJ, N·bromoacetyl.(lzIlT~; 3,3'.T~, 3,3'..<fi-
iodothyronine. 
Correspondence: TJ. Yis.~er. Dep:mment of internal Medicine III. 
Erasmus University Medic:li School. P.O. Box: 1738. 3000 DR ROlter· 
dam. Netherland~. 
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labeling of ID-I in rat liver microsomes with N-
bromoacetyl iodothyronine derivatives has identified 
an enzyme subunit of Mr ::::: 27 kDa [2-5]. 
As 10-1 plays a key-role in thyroid hormone 
metabolism. its characterization has been subject of 
extensive investigation. Several attempts have been 
made to isolate 10-1 from rat liver or kidney micro-
somes. but purification has at best been modest [6-81. 
which is explained by the fmdings that ID~I is a very 
hydrophobic [5]. low-abundance [9.10J. integral mem~ 
brane protein that is probably composed of two sub-
units [8]. aoning strategies using antibodies against 
solubilized ID-I have led to the incorrect identification 
of ID-I as protein disulfide isomerase (POI) (111. a 
protein completely different from ID-I [3]. 
The purpose of the present study was 2·fold, i.e. to 
investigate the homology between ID~I of different 
species and to explore alternative sources for the isola-
tion of the enzyme. This was done by detennination of 
ID-I activity and content in liver microsomal fractions 
from various animals by enzyme assays and affInity-
labeling with BrAc[I2SIlT). 
Materials and Metbods 
Materials 
[3' .s'_I2SIJrT) and [3'- l:SIlT) ("" 1700 Ci/mmoJ) were 
obtained from .A.rnersham (Amersharn. UK); unlabeled 
iodothyronines from Henning (Berlin. Germa.ny); 
dithiothreitol (DIT) and PTU from Sigma <St. Louis. 
MO. USA); electrophoresis grade SDS-PAGE reagents 
from Bio-Rad (Richmond. IL. USA); BCA protein 
assay reagent from Pierce Europe (Oud Beijerland. 
Netherlands): Mr markers and Sephadex LH~20 from 
Phannacia (Uppsaia. Sweden);' and Coomassie brilliant 
blue R~250 from Merck (Darmstadt. Germany), 
Preparation of microsomes 
Liver microsomes were prepared in buffer A (10 
roM Tns..HO. pH 7.4. 3 mM EDTA and 3 mM DTT) 
as previously described [121 and stored at - 70°C. Pro-
tein content was measured by Pierce BCA protein 
assay. using bovine serum albumin as the standard. 
Deiodinase assay 
ID-I activity was determined by incubation of the 
appropriate amount of microsomal protein for 20 min 
at 3'?C with 10,u.M rT3 and 75 nei (lzsIlrT3 in 200,tt1 
buffer B (0.2 M phosphate. pH 7.2, 4 mM EDTA and 
10 mM DTI). The reaction was stopped by placing the 
samples on icc and adding 750 ,ttl of 1 M HCI. Re~ 
leased lZSr- was separated from iodothyronines on 
Sephadex LH-20 as described before [13], and the data 
were corrected for non-enzymatic deiodination as de~ 
tennined in incubations without microsomes. For cal-
culation of ID-I activity, random labeling of the 3' and 
5' positions of [1Z5I]rT3 was taken into account. 
Synthesis of BrAc[I2sI]T) and nonradioactive BrAcT) 
The affinity labels were pIepared essentially as pre-
viously published [2]. HPLC analysis demonstrated that 
the purity of BrAc[1::SI]T3 was at least 85% with unre-
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Species differences in type I deiodinase 
acted [lZ5I]T3 as the main contaminant, while nonra-
dioactive BrAcT) was more tban 95% pure. 
Affmily-/abding 
Solutions of BrAc[IZSnf3 and BrAcT) in ethanol 
were pipetted into an Eppendorf tube and the solvent 
was evaporated at 42"C under a stream of nitrogen. 
The desil'ed amount of microsomal protein in 100 p.l 
buffer A was added to tbe residue and the mixture was 
vortexed for 30 s. After further incubation for 10 min 
at 3TC, labeling was stopped by addition of 50 p.i of 
SDS-sample buffer containing 30% ,B-mercaptoethanol 
and treatment for 5 min at 10Q"C. Proteins were sepa-
rated overnight by SDS-PAGE in a 14 em 10% T, 3% 
C gel. overlaid by a 2 em 3% T, 3% C stacking gel [14]. 
With all samples tested, over 90% of applied radioac-
tivity had moved into the separation gel. Gels were 
stained with Coomassie brilliant blue R-250, dried un-
der vacuum and autoradiographed at -70"C with Ko-
dak T-MAT G film. After autoradiography, lanes were 
excised from the gel and cut into 1 nun fractions. which 
were counted for radioactivity. Apparent molecular 
mass (Mr ) was detennined by interpolation with pro-
tein markers. 
Deiodinase content 
The ID~I content of the microsomes was calculated 
by saturation analysis of the progressive labeling of 
protein in the ::::: 27 kDa band with increasing concen~ 
trations of BrAcT), assuming that one molecule of 
ID-I can only bind one molecule of BrAcT,. Two 
methods were used for this purpose. First. data were 
analyzed by a direct linear plot of the amount of 
BrAcT, incorporated in the ::::: 27 kDa band as a func-
tion of the amount of BrAcT, added, similar to the 
B Hum Rat Mou Rab Oog: Cow Pig She Goa Chi Duc 
kOa 
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'" - -,,':"';;fdi~/~ 
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Fig. 1. Labeling of liver microsomal proteins of different species with BrAcP:5rrrJ • Microsomes (50 p.g protein) were reacted for 10 min at 37 C 
with 0.1 poCi BrAc[1:51rrJ in the absence (A) or presence (B) of 10 p.M rT, and 100 p.M PTU as described. in Materials and. Method$. After 
5DS·PAGE. fUm was exPoscd. for 17 h. 
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method described by Safran et a1. [9]. At each BrAcT) 
concentration used. labeling of the "" 27 kDa band in 
the absence of rT3 and P11J was corrected for the 
nonspecific labeling and background activity observed 
after labeling in the presence of rT3 and PTU. The 
maximum value of the thus calculated specific labeling 
of the "" 27 kDa band obtained at high BrAcT) con~ 
centrations represents the ID~I content of the micro~ 
somes. Second. data were analyzed in a Scatchard-like 
plot of the radioactivity in the "" 27 kDa band divided 
by the radioactivity not associated with this band as a 
function of the amount of BrAcT 3 incorporated in the 
:::: 27 kDa band. Non-linear plots were resolved into 
two linear components according to the method of 
Rosenthal [15]. The second component represents 
non-saturable and. thus. nonspecific BrAcT3 incorpo-
ration in the == 27 kDa band. The first component 
reflects saturable and. thus. specific BrAcT 3 labeling of 
the == 27 kDa band. the maximum of which is deter~ 
mined by the intercept with the horizontal axis. repre~ 
senting the ID~I content of the microsomes. 
Reproducibility 
Liver samples were obtained from 2 or 3 animals-of 
each species. but the results of the ID~I assays are 
representative compared with more detailed studies. 
e.g .• human [12], rat [1] and chicken [161. Unless stated 
otherwise. the data shown are from representative ex-
periments which were repeated 2 or 3 times with 
closely agreeing results_ 
Results 
After reaction of BrAc[1~I]T3 with liver microsomes 
fonowed by SDS-PAGE. two prominent radioactive 
proteins of == 56 kDa and == 27 kDa are observed in 
an 11 species examined (Fig. lA). It has been demon-
strated with rat liver microsomes that the 56 kDa band 
represents labeling of PDI. and that labeling of the 27 
kDa subunit of ID-I is completely inhibited by coin~ 
cubation with the substrate rT 3 and the uncompetitive 
inhibitor PTU [3]. The combination of rT) and PTU is 
much more effective in inhibiting the BrAcT) labeling 
TABLE I 
Ciw.racferistics of 1001 in liver microsomes of diffcN!tU species 
BrAcT3 
(pmol) 
kDo 
94 _ 
o .8 3.8 12.8 44.8 
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Fig. 2. Effect of increasing amounts of unlabeled BrAcT, on the 
labeling of rat liver microsornes by BrAc[I~lrrl' Microsomes (l00 
1'-& protein) were reacted for 10 min at 37"C with '0.2 pmol W.25 I'-CD 
BrAc!I2$ITr, in the presence of 0, 0.8, 3.8. 12.8 and 44.8 prnol of 
BrAcTl and in the absence (A) or presence (8) of 10 I'-M rTl + 100 
I'-M PTU. After SDS-PAGE. film was exposed for 16 h. 
of ID~I than either rT) or PTU alone. because of the 
formation of a stable. inactive P11J-enzyme complex 
which only occurs in the presence of substrate. ID~I 
was identified in other species by comparison of label-
ing patterns in the absence (Fig. lA) and presence 
(Fig. 18) of 10)J,M rTj and 100)J.M PTU. Labeling of 
the == 56 kDa protein was. not inhibited by these com~ 
pounds. BrAcT 3 labeling of the "" 27 kDa protein was 
completely prevented by rT 3 plus PTU in all microso~ 
mal preparations except in dog liver microsomes where 
labeling was reduced by about 50%. The M r of ID-I in 
liver microsomes of the different species is given in 
Table I. showing a narrow range of 25.7 (chicken) to 
29.1 kDa (cow). 
Liver microsomes were reacted with 0.2 pmol 
BrAc[12!i11T3 and increasing amounts of BrAcT). In 
order to determine nonspecific incorporation of 
BrAc[12!iIlT3 in ID-I, these reactions were also done in 
Molecular mass is given in kDn; 10-1 content in prnol !D-I/mg protein (mean of two experiments): 10-1 activity in pmol rT ,Imln per mg protein 
(mean±S.D.): turnover number· in min-I. 
Human Ro< Mo= Rabbit Dog C~ Pig Sheep Goal Chicken Duck 
M, 2M 28.2 2SJ 17.5 16.1 29.1 ?:l.6 16.1 16.6 25.7 260 
Content 0" 3.65 0.65 055 4.74 U5 0.67 0.44 0.79 0.36 0.28 
Activity 341±9 3022±8l 233±2l S60± 16 369±29 311 ±27 267±29 l16±15 836=22 231 =28 130±:6 
Turnover 
number 669 828 359 1019 7S 270 399 264 1059 642 '64 
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Fig. 3. Saturation analysis of the progre:;sive incorporation of BrAcT> in rat liver ID-I with increasing amounts of added BrAcTJ • (A) Direct plot 
of BrAcT J incol'pOT:ltion in the '" 27 kDa band as a function of the amount of BrAcT J added in the absence (-) or presence (+) of 10 .u-M rT J 
and 100 ""M PTU. The difference between these curves (Al represents specific BrAcT, incorporation in ID-l. {Bl Scatchard.Hke plot of 
radioactivity in the" 27 kDa band divided by radioactivity not associated with thL~ band as a function of the amount of BrAcT} incorporated in 
the .. 27 kD:l band. Re:wlution of th<: Cl:Irvc in a s;J,turable and a non·saturable component was done as described under Materials and Methods.. 
the presence of 10 fotM rT3 and 100 fotM PTU. Fig. 2 is 
an example of the SOS-PAGE analysis of such an 
experiment with rat liver microsomes. The autoradio-
gram in Fig. 2A demonstrates that incorporation of 
BrAc[l1SIlTJ in the =:: 27 kDa band in the absence of 
rT3 and PTU is progressively inhibited with:non-radio-
active BrAcT), indicating that this is largely a saturable 
process. The results obtained after SDS-PAGE of mix-
tures containing rT3 and PTU (Fig. 2B) show very little 
nonspecific labeling of the =: 27 kDa band. The dose-
dependent BrAcT) incorporation was determined from 
the radioactivity in the =:: 27 kDa band and subjected 
to two methods of saturation analysis. Fig. 3A is the 
direct plot of BrAcT) labeling versus the amount of 
BrAcT) added. BrAcT) incorporation in the presence 
of rT3 and PTU is a linear function of the amount of 
BrAcT) added and is subtracted from the total BrAcT) 
incorporation occurring in the absence of rT) and 
PTU. The thus determined specific BrAcT) incorpora-
tion in the =:: 27 kDa band reaches a plateau at in-
creasing BrAcT) concentrations, which corresponds to 
an ID·I content of 3.74 pmol/mg microsomal protein. 
Fig. 3B is the Scatchard-like plot of the BrAcT:I incor-
poration in the == 27 kDa band in the absence of rT3 
and PTU. The intercept of the saturable component of 
this plot with the horizontal axis represents the maxi-
mum specific BrAcT) incorporation. corresponding to 
an ID-I content of 356 pmol/mg microsomal protein. 
Therefore. the results of both analyses are in excellent 
agreement. 
The ID-I contents of liver microsomes from other 
species were determined similarly. Fig. 4 shows the 
SDS-PAGE patterns of human liver microsomal pro-
teins labeled with varying amounts of BrAcT) in the 
absence or presence of rT3 and PTU. The graphical 
analysis of these results is depicted in Fig. 5. indicating 
once again the close agreement between the two meth-
ods for the determination of the maximum specifiC 
BrAcT) labeling of the =:: 27 kDa band. The thus 
calculated ID-I content of human liver microsomes was 
found to be significantly lower than in the rat, i.e. 0.51 
pmol/mg protein. Dog liver microsomes provided the 
single exception where ID-I content could not be de-
termined directly. The autoradiograms in Fig, 6 
demonstrate that the concentration-dependent BrAcT) 
labeling of the =:: 27 kDa band was only partially 
BrAcT3 (pmol) 
kDo 
94 _ 
67 -
o .8 3.8 128 44.8 
'01"""-""'''_-
43 _II! ...........  
30- __ ••• 
20 -14 ______ _ 
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-
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Fig. 4. Effect of increasing amountS of unlabeled BrAcT, on the 
labeling of human liver microsomes by BrAcrt~UrJ in the absence 
(A) or presence (B) of 10 p.M rTl + 100 J.4M PTU. For further 
details.. see Fig. 2. 
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inhibited by addition of rTJ plus PTV. in agreement 
with Fig. 1. Therefore. the direct plot of these data as 
shown in Fig. 7 A could not be used to determine the 
ID-I content of these microsomes. However, specific 
BrAcT) labeling of ID-I in dog liver microsomes was 
determined accurately by Scatchard-like analysis as 
shown in Fig. 7B. corresponding to an enzyme content 
of 4.74 prool/mg protein. The ID-I contents of liver 
microsomes from the different species are summarized 
in Table I. It is clear that enzyme contents of rat and 
dog liver microsomes are markedly higher than in all 
other species examined. 
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Fig. 6. Effect of increasing amounts of unlabeled BrAcT) 011 tbe 
labeling of dog liver mierosomes by BrAe[l2Srrr) in tbe absence (A) 
or presence (B) of 10 J.'M rT3 + 100 J.'M PTU. For further details. 
see Fig. Z. 
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ID-I activity was detennined at 10 ,u.M rT3' al-
though in most species 1 ,u.M rT;; proved to be a 
near-saturating substrate concentration except for dog. 
The lower affinity of rT 3 for dog JD-I is supported by 
estimations of its Km value of :::: 5 ,u.M (T.J. Visser. 
unpublished work) as opposed to :::: 0.1 ,u.M in human 
[12], rat [1] and chicken [16] and is further reflected by 
the finding that dog ID-l is still labeled by BrAc(I2SI]T3 
in the presence of rT;; and PTU (Fig. IB). The results 
of the ID-I assays are presented in Table I. Lowest 
ID-I activity is observed in sheep liver and highest 
activity in rat liver. Division of 1O¥I activity by ID-I 
content yields turnover numbers for the enzymatic 
deiodination of rT;;. Table I shows that turnover num-
bers val)' between 264 and 1059 min -1 except for dog 
ID~I which has an extremely low turnover number of 
78 min-I. 
Discussion 
10-1 has been studied extensively in liver of humans 
[12]. rats [11. dogs [17] and chickens [16]. Less informa-
tion is available about the enzyme in pig [18], cow [19]. 
mouse [20]. duck [21] and sheep [22] liver. while very 
little is known about the deiodinase in rabbit and goat. 
Available evidence indicates a high degree of similarity 
between liver ID~I enzymes from different species. 
with the following characteristics: Ca) localization in 
microsomal fraction: (b) catalysis of both 5~ and 5'~de" 
iodination~ (c) stimulation of deiodinase activity by 
small thiol-containing compounds such as DTT: Cd) 
uncompetitive inhibition by ?TV: (e) preference for 
rT;; as the substrate~ and CO facilitated deiodination of 
sulfated iodothyronines [1]. The present findings ex-
tend these previous observations by demonstrating that 
BrAcT;; is an equally effective affinity.label for ID~I 
from different species with a narrow range of subunit 
Mr' Recently a cDNA encoding rat 10-1 has been 
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Fig. 7. Satur:nion analysis of the: progrClisive labeling of dog liver ID-I with increasing concentrations of BrAcT) by (A) direct plot or (B) 
SQtchard·like plot of the results depicted in Fig. 6. For further details, see Fig. 3. 
cloned using the Xenopus oocyte expression system 
[23]. From the DNA sequence it is deduced that ID-l is 
a hydrophobic protein with a molecular mass of 29.7 
kDa and contains a seienocysteine residue. 
It has been demonstrated that ID-! of rat liver and 
kidney is highly susceptibLe to inhibition by iodoac-
etate. showing that fLM concentrations of this· reagent 
are sufficient to completely inactivate the enzyme [10]. 
This inactivation has previously been thought to result 
from the covalent modification of a catalytically active 
sulfuydryl group. but it is now realized that this is 
probably due to carboxymethylation of the seienocys-
teine residue [23]. It remains to be seen if the conve-
nient labeling of ID-I with BrAcT, is based on reaction 
with the same functional group in'aIl species examined. 
The finding that BrAcT:; labeling, which is prevented 
by rT, and PTU [31. results in a loss of enzyme activity 
suggests that the enzyme active site is modified upon 
labeling. 
Two obsel'Vations in the present study deserve fur-
ther comment. Firstly, in addition to the == 27 kDa and 
== 56 kDa proteins. another prominent band (Mr 32 
kDa) was observed after labeling of pig liver micro-
somes (Fig. 1), which also showed saturation with in-
creasing BrAcT) concentrations (not shown). A similar 
faint band was observed in liver microsomes of other 
species (Figs. 2. 4 and 6). Preliminary evidence suggests 
that this may represent labeling of a type III iodothyro-
nine deiodinase (ID-III). a' low K;" 5-deiodinase with 
preference for T). since (a) pig liver microsomes pos-
sess significant ID-III activity, and (b) a similar == 32 
kDa band was observed in rat brain and placenta. 
tissues with high ID-I1I activities (1). However. the 
relationship of the == 32 kDa protein to ID-lII remains 
to be determined. Secondly. the labeling of dog liver 
ID·I with BrAcT) is inhibited much less effectively by 
the presence of rT3 and PTU than the ID-J labeling in 
other species. This is compatible with the findings that 
the substrate specificity of dog liver ID-I differs from 
the enzymes of human [121. rat [1] and chicken [16] 
liver. indicating a lesser preference for rT:; over other 
iodothyrorunes as the substrate (Ref 17: T J. Visser. 
unpublished work). 
In conclusion. affinity-labeling with BrAcT:; suggests 
a high degree of homology between different species 
with respect to subunit structure of liver type I iodothy-
ronine deiodinase. 
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Chapter 4 
Impairment of the Selenoenzyme Type I Iodothyronine 
Deiodinase in C3H/He Mice* 
CHRISTIAN H. H. SCHOENMAKERS. INGRID G. A. J. PIGMANS, ALAN POLAND, AND 
THEO J. VISSER 
Department of Internal Medicine III (C.H.H.S .• I.G.A.J.P., T.J. '\1.), Erasmus University Medical Schoo~ 
3000 DR &tterdam. The Netherlands; and McArdle Laboratory for Cancer Research (A.P J. Un.iversity of 
Wiscoll$in, Madison, Wisconsin 
ABSTRACT 
Type I iodothyronme deiodinase (ID·I) activity ill impaircd. in C3HI 
He (GaH) miCfl com.pared with BALB/c and C57BL/6N (CS7) mice. In 
this study we compared ID-I activity and protein labeling with N· 
bromoacetyl-['~IJT~ (BrAc['~I]T3) oX' ~Se in liver microsomes of C3H 
and C57 mice. Hepatic ID·I activity in C3H mice was higb.ly variable 
with a mo:xiiru:l of only 18% of toot in C57 mice. However, C3H mice 
had normal serum. T. and T a levels, although serum reveroo Tawas 
incronaed. The ZS·kilodalton (kDa) ID·I protein W0.6 identified by 
sodium dodecylsulfute-polyacry1am.ide gel electrophoresis of BrAc(I.26IJ 
Ta-labeled micw80mes. Labeling of this protein wos' virtual.I.y unde· 
tectable in C3H sam,pies with low enzyme activity. ID·I activity in liver 
microsomes WIl8 3trongly decrell800 in Se-dcficient mice, which WQ3 
M ANY processes involved with growth, development, and metabolism in vertebrates are controlled directly 
or inclirectly by the thyroid hormone T, (l, 2). These actions 
are initiated by binding of TJ to nuclear receptors, which 
interact with cis-acting elements, modulating the expression 
of target genes (l, 2). Most TJ in the plasma of humans and 
rats originates from the peripheral 5' -deiodination of the 
prohormone T~, which is the major secretory product of the 
thyroid (3, 4). Alternatively, T4 is inactivated by S-deiodina-
tion to reverse TJ (rT3) (3,4). 
Three types of enzymes catalyzing the deiodination of 
thyroid hormone have been identified (3,4). Type I iodothy-
ranine deiodinase (ID·I) is found in liver, kidney, and thy-
roid. and is responsible for the major part of peripheral TJ 
production. However, the enzyme catalyzes both 5- and 5'-
deiodinations and shows preference for rTJ as the substrate. 
ID-I is located in the endoplasmic reticulum of liver cells and 
requires thiol compounds as cofactor (3, 4). It is specifically 
inhibited by 6-propyl-2-thiouraci1 (PTU) and by N-bromo~ 
acetyl-T3 (BrAcT3), which has proven to be a very useful 
affinity label of this enzyme (4, 5). Type II iodothyronine 
deiodinase (lD~1I) catalyzes exclusively 5' -deiodination and 
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parnlleloo by admstic decreas.e in BrAcr:IArrrs·lnbeling of the 28·kDll 
band compared with control mice. Labeling of ID·I with '1:ISe was 
demonstrated by sodium dode9'l su!fat&-polyacrylamide gel electropbo-
resis of liver microsomes of ["'Sejselenite·injected mice. ~'Se labeling 
oftbe zg·kDa band wll8ll'llLfkedly higher in Se-dcficient than in control 
mice and WIl8 also markedly higher in C57 than in C3H mice. Finally, 
liver ID·I messenger RNA (mRNA) was meWiured on Northern blots 
using a rat ID·I complementmy DNA probe. Me83enger RNA levels 
correlated strongly with ID·I activity, 3howing a significant decrease 
in C3H mice. We conclude that in mice, like in rats and hllm8.Il3, ID·I 
is a selenoprotein. ID·I activity is impaired in C3H mice because of 
decrellfloo transcription of the ID· I gene or reduced stability of the 
mRNA.. (Endocrinology 132: 357-361, 1993) 
is found in brown adipose tissue, pituitary, and brain (3, 4). 
Type III iodothyronine deiodinase (lD-III) catalyzes the 5-
deiodination of thyroid hormone and is present predomi-
nantly in brain and placenta (3, 4). 
Recently, the complete nucleotide sequence of rat liver ID-
I (6) and part of the sequence of the human enzyme (7) have 
been reported, showing that in both species ID-I contains a 
selenocystcine residue. In rats, the amount of ID·I in liver, 
kidney, and thyroid is greatly influenced by the Se status, 
ID-I activity being markedly decreased in Se-deficient ani-
mals (8, 9). We have previously demonstrated that the struc; 
tural and enzymatic properties of liver ID·l are very similar 
between different species with exception of the dog (10). 
Hepatic ID-I content was found to be much lower in BALBI 
c mice than in rats (10). However, large differences have also 
been observed between different mouse strains, with mark-
edly impaired ID·I activity in C3H/He (C3H) mice compared 
with BALB/c and C57BL/6N (C57) mice (11). In the present 
study ID-I activity was compared with protem labeling with 
BrAce:!:lI]TJ or :'3Se in liver and kidney microsomes of C3H 
and C57 mice. It was further investigated if the impaired ID-
I activity in C3H mice could be due to alterations in ID·I 
gene expression. 
Materials and Methods 
Materials 
Nal~' (-450 Ci/mol), [3',5'·'''I]rT" .md [3'-'::'I]T, (1700 Ci/ 
=01) were obtained from Amersham (Amersham, UK); unlabeled 
iodothyt'oninCS from Henning (Berlin. Germany); dithiothreitol (D11) 
:md PTU from5igma (St. Louis, MO); Sodium dodecyl sulf;:J.te-polyacryI-
Impaired type I deiodinase in C3H/He mice 
~de gel electrophoresis (50s-PAGE) reagents from BiolQd (Rich-
mond, CAl; SCA Protein As5;ly Reagent from Pierce Europe (Oud 
Beijerland. The Netherlands); molecular mass markers and Sephadex 
LH-20 from Phannaci.l (Upps.ilil, Sweden); and Coomassie brilliant blue 
R-250 from Merck (Darmstadt, Germany). 
Mice and diets 
Tw<rmonth-old (25-30 g body wt) mice were obtained as follows: 
BALB/cAnNHSD, C3H/HeNHSD, and C57BL/6NHSO mice from &t-
Ian Sprague Dawley (Indianapolis, IN; CH/Ouj mice from Iffa Credo 
(L'Arbresle. France); and e3H/He, mice from The Jackson L.lbomtory 
(Bar HarbQr, ME). All mice were kept in plastic cases with wood chip 
bedding at a constant temperature and humidity and a 12 hIll h light! 
dark cycle. MilliQ (Millipore. Bedford, MAl-purified water and food 
(diet AMn 1410, Hope Farms, Woerden, The Netherlands) were avail-
,)ble ad libitum. Se-deficient food supplemented with vitamin E (diet 
170698) and control Se-sufficient food (same diet supplemented with 
0.2 ppm sodium selenite, diet 170699) were purchased from Teklad Test 
Diets (Madison, VVI). &- deficiency was induced in C3H and C57 mke 
by feeding dams during pregnancy and lactation with the 5c-deficient 
diet. After weaning, the newboms were kept on the same diet for at 
least 8 weeks. Control groups received the Se-supplemented diet. 
Preparation. of microsomes 
Mice were killed by cervical dislocation. and livers, kidneys. and 
brains were isolated. Microsomes were prepared in 10 roM 1ris/HCl (pH 
7.4).3 trIM EDTA. and 3 trIM OTT (TED buffer) as previously desa:ibed 
(12) and stored at -70 C. Protein content was measured with the BCA 
protein assay, using B5A olS the standard. 
Affinity labeling 
An ethanol solution of BrAc{mI]T), prepared as previously described 
(13), was transferred to.ln Eppendori tube, and the solvent was evap-
or.lted under a stream of nitrogen at 42 C. A microsomal suspension In 
100 .u TED buffer was <ldded to the residue, and the mixture was 
vortexed for 30 sec. After further reaction for 10 min <It 37 C, l.lbeling 
was stopped by addition of 50 1'1 50S $;Imple buffer contJining 30% {3-
mercaptoethanol <lnd treatment for 5 min <It 100 C. Proteins were 
separatccl by overnight 50S-PAGE in a 14-= 10% T, 3% C gel. [T "" 
totll concentration (wt/vol) of acryiJmide + bisacryl;unjde: C ... concen-
tration of bisacryiJmide (wt/vol) as percentage of Tj, overlaid by a 2· 
em 3% T, 3% C stacking gel (14). Gds were stained with Coornassie 
brilliant blue R-250 <It 60 C and dried under vacuum. Autoradiography 
of labeled proteins was done by exposure to Kodak T-MAT G film 
(Eastm.ln Kodak Co .. Rochester, NY) at .70 C. Apparent molecular mas:; 
W.l5 determined by interpolation with protein markers. 
~~ Se labeling 
Sc-deiicient or control mice received a single ip injection with 50 I'Ci 
Na:"'SeO~. After 4 daYS the arnmals were killed, and liver microsomes 
were prepared for ex.ainination of "Se_l<lbeled proteins by 50s-PAGE. 
DeicdilUL.~e assays 
10·1 activity was measured by incubation oi 2 I'g liver or kidney 
microsomal protein for 60 min at 37 C with 0.1 jLM rT) and i5 nO [1~J 
rT, in 200 1'1 0.2 M phosphate (pH 7.2), oj. mM EDTA, and 5 IJ\M OTT .lS 
previously descnbed (10). The reactions were stopped by addition oi 
i50 I'll M HCl on icc. The mr- released was isolated on Scphadex LH-
20 and conectccl for nonenzvrnatic deiodination dete=ined in incuba· 
tions without mlcrosomes. lO·m activity was me.l5ured by mcubaoon 
of 200 1'7" br.rin microsomal protCln for 60 mm at 37 C with 1 !'1M T, Jnd 
is nO e I]T, in 200 "I 0.1 M phosphate (pH 7.2), 2 mM EDTA,.md 10 
mM OTT. The reactions were stopped by Jddition of 300 JJl methanol 
on Ice. After centrif~atlon of preciPltJted proteins, the supernatants 
Were analyzed for [I' I]3,3'.diiodothyronine fonnaoon by HPLC on a 
100 x 3.0 mm Chromspher C18 column (Chrompack, Mlddelbutg. The 
Netherlands), eluted with a 45:55 (vol/vol) mixture of methanol and 20 
trIM ammonium·acetate (pH 4.0) at a flow of 0.8 ml/min. Paxallel 
incubations were done with 1 jLM T), which saturates the low-KM: ID-m 
but not the high.KM ID·I (3) (KM .. /'.fi.chaeJ.is..Menten Constant), show· 
ing negligible type 1 .md nonenzymatic dei~tion of T, by brain 
nucrosomes. 
Northern blot analysis 
RNA WolS isolated from liver by acid guanidinium thiocyanate-
phenol·chloroform extraction (15). Samples of 20 I'S RNA were sepa" 
rated by <lgarose gel electrophoresis and transferred to a Gene5c:reen 
hybridization transfer membrane (DuPont Boston, MA) (16). Rat ID-I 
(riD-I) complementary DNA (cDNA) probe (6) was kindiy donated by 
Drs. Marla Berry and P. Reed Larsen (Harvard Medical SchooL Boston.. 
MA) and radioactively labeled using random primers and Klenow po-
lymerase (17). After hybridization at 42 C in the presence of 50% 
fonnamide and 6% dextran sulfate (18). <lutoradiographs were quantified 
using .l BioRad model 620 video densitometer. In order to standardize 
the 10-1 messenger RNA (mRNA) signal, the blots were stripped for 5 
min at 100 C successively with O.lX sec (Ix sse.,. 0.15 M NaO, 0.015 
M Na citrate. pH 7.0) and water, and hybridized with a ,6·actin eDNA 
probe. 
Results 
In both C3H and C57 mice ID-I activity was much lower 
in kidney than in liver microsomes (Table 1), which is in 
contrast to rats and humans, where kidney and liver display 
similar ID·I activities (3, 4). Mean ID·I activities in both liver 
and kidney miaosomes were significantly lower in C3H than 
in C57 mice (Table 1). In contrast, ID-III activity in brain 
microsomes was the same in C3H and C57 mice Crable 1). 
Hepatic ID·l activity was not uniformly impaired in C3H 
mice but showed a marked heterogeneity independent of the 
supplier. In this study, ID·! activity was determined in a total 
of 47 C3H mice and 25 C57 mice. In each experiment, 
enzyme activity in individual mouse livers was expressed. as 
a percentage of the mean control value in 07 mice, and the 
results are presented as histograms in Fig. 1. This figure 
dearly demonstrates the widely different distribution of he-
patic ID-I activity in C3H and 07 mice. ID-I activity is 
severely impaired in most C3H mice, but occasionally fairly 
normal levels are encountered, i.e. similar to those in 07 
mice. 
Todothyronines were measured in serum by specific RlAs. 
Table 2 shows that low ID~I activity in C3H mice is not 
associated with changes in serum TJ or T~ concentrations. 
However, serum rT J levels are significantly higher in C3H 
mice than in C57 mice. 
Figure 2A shows typical examples of the labeling patterns 
TABLE 1. lodothyronine deiodinnse activities in rnnle C57BL/6N 
and C3H/He mice 
ID·I in liver \1'1 '" 12) 
ID·I in kidney (n = 6) 
ID·m in brain (1'1" 4) 
C57BL/6N 
35.; ± 9.6 
;.6 ± 1.6 
41.2 ± 2.1 
C3HIHe 
5.6 ± 6.4" 
2.2 ± O.S" 
38.5 ± 14.0 
ID-I und ID·III activity are given in picomoles of rT, per min/mg 
protein and femtomoles of T, per min/mg protein. respectively (mean 
::!:: SOl. 
• P< 0.001. 
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FIG. 1. Histograms of the distribution of hepatic ID·I activity in 47 
C3H/He and 25 CS7BL/6N mice. Liver microsomal ID-I activities in 
individuul mice were expressed WI a percentage of the mean enzyme 
activity of control CS7 mioo in each eXperiment. The roaults represent 
the number of mice with ID-I activities ranging from 0-20%, 20-40%, 
etc.. of controL 
TABLE 2. Serum iodothyronine concentratioIlll in male C57BL/6N 
and C3H/He mice 
T, 
T, 
,'T, 
CS7BL/6N 
29.0;:: 9.3 
0.78:!: 0.23 
0.05 ± 0.02 
C3H/He 
31.6:!;: 7.5 
0.88 ± 0.27 
0.17 ± 0.06" 
Coneontrntions are given in nanomoles per liter (mean ± SD, n .. 
12). 
• P< 0.001. 
obtained after reaction of BrAce::5I]TJ with liver microsomes 
of CS7 and C3H mice, followed by SDS·PAGE and autora-
diography. Using rat liver microsomes, the prominent 56-
kilodalton (kDa) band has previously been identified as 
protein disulfide isomerase (5). The 28~kDa band represents 
ID-I (5, 10) and is labeled to highly variable extents in C3H 
samples. Figure 2S shows that BrAc[l~!JT l incorporation in 
the 28-kDa band closely parallels ID~I activity. The virtually 
undetectable labeling of this protein in C3H liver samples 
with low ID-I activity suggests a strong decrease in the 
amount of enzyme. 
In both C3H and C57 mice Se deficiency resulted in a 
profound decrease in hepatic ID-I activity compared with 
the control groups fed the Se-supplemented diet (Table 3). 
The data presented in Table 3 for Se-sufficient C3H mice are 
another example of the wide variation in ID-I activity in this 
strain, ranging from grossly impaired in two mice to levels 
similar to those in control C57 mice in two other animals. 
Figure 3 compares the ID-I activities of liver microsomes of 
Se-deficient and control C57 mice with the labeling patterns 
obtained after reaction of the corresponding samples with 
BrAc[1,zsI]TJ. The results demonstrate that the decreased ID-l 
activity induced by Se deficiency is paralleled by a decrease 
in the BrAcezsI]T, labeling of the 28-kDa band. 
Incorporation of 7!lSe in the 28-kDa ID-I protein was 
detected by SDS-PAGE of liver microsomes of C~Selselenite-
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FIG. 2. A. Labeling patterns obtained o.ftcr reaction of 50 ).tg liver 
microsomal protein from mule C57BL/6N and C3H/He mice with 0.05 
I'Ci BrAc['2lII]T,.. After SDS·PAGE. film was exposed for 26 h. B. ID-
I activity of the same microsomal oomples shown in A. 
TABLE 3. Liver ID-l activity in control und ~-deficient mule 
C57BL/6N and caHJHe mice 
C57BL/6N 
C3H/He 
Control 
52.1 == 9.3 (n -1) 
40.5 ;t 35.0 (n "" 5) 
Se·defici~nt 
12.8 ± 1.5" (n = 4) 
3.9 ± 0.1 (n '" 4) 
ID-! activity is given in picomoles of rT, per min/mg protein (menn 
±SD). 
" P<O.OOl. 
injected mice (Fig. 4). The 75Se labeling of this band was 
markedly higher in Se-deficient than in Se~sufficient mice 
and was also markedly higher in C57 than in C3H mice. 
To investigate if impaired ro-I activity in C3H mice is due 
to a structural defect in the 10-1 gene or to decreased expres-
sion of the gene, Northern blot analysis of C3H and CS7 
liver RNA was performed using an rID-! cDNA probe. Figure 
5 shows that differences in ID~I activity are closely paralleled 
by variation in liver ID~I lORNA (r = 0.82, P < 0.005). The 
mean ID-I mRNA level is significantly lower in C3H than in 
CS7 mice (0.9 ± 0.2 us. 1.8 =. 0.5; P < 0.005). When the ID· 
I mRNA signals were expressed relative to those for tJ-actin 
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mRNA, the resultant ratios were also significantly lower in 
C3H than in C57 mice (0.62 ± 0.19 vs. 1.24 ± 0.66; P < 
0.05). 
Discussion 
The presenJ: study represents the fIrst full description of 
the defect in ID-I activity in an animal strain. The magnitude 
of this defect is not uniform in C3H mice but ranges from 
severely impaired to occasionally the same levels as observed 
in control C57 mice. In this initial work the emphasis was 
on the characterization of the defect rather than a detailed 
analysis of its biological consequences. The lack of a decrease 
in serum TJ relative to serum T4 in C3H mice with impaired 
ID-I activity is in contrast to findings in rats where the serum 
T~/T~ ratio is strongly reduced if ID-I activity is inhibited by 
PTU administration or Se deficiency (3, 4, 8, 9). This may be 
explained by: 1) a lesser importance of 10-1 for plasma TJ 
production in mice, which is supported by the much lower 
hepatic and renal enzyme activities compared with those in 
rats; and/or 2) a compensatory increase in alternative path-
ways of TJ production, i.e. cfuect thyroidal TJ secretion or T4 
to TJ conversion by JD-Il in tissues such as the brain. How-
ever, in the absence of data on TJ secretion and peripheral 
production rates as well as of ID-IT activity determinations, 
the importance of these routes remains speculative. The 
higher serum rTJ levels in C3H mice compared with C57 
mice are in keeping with the view that JD-I is important for 
the clearance of plasma rTJ (3, 4). 
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M£initylabeJing of the 28-kDa ID-I protein with BrAc[IZSI] 
TJ is decreased in C3H compared with CS7 mice. Although 
this could be due to a lower affmity of the label for the 
enzyme in C3H mice, the correlation between the extent of 
labeling of the 28-kDa protein and rD-I activity strongly 
suggests a decrease in the amount of enzyme. This is further 
supported by the results of the analysis of ID-I labeling with 
75Se as well as the quantification of ID-I mRNA (see below). 
The decreased rD-l activity induced by Se deficiency is 
paralleled by a decrease in the BrAc[125I]T~ labeling of the 
28-kDa band representing ID-I. These findings confirm pre-
vious observations in rats (8, 9), indicating that Se deficiency 
results in a decrease of hepatic IO-I content. 
7SSe labeling of the 28-kDa band was markedly higher in 
Se-deficient than in Se-sufficient mice, which is explained 
by the higher specific radioactivity of the selenium available 
for incorporation into selenoprotein. 75Se labeling of the 28-
kDa protein was also markedly higher in C57 than in C3H 
mice. These findings suggest that: 1) mouse liver ID~I is a 
selenoprotein in accordance 'IN'i.th the structure reported for 
rat and human ID~I (6, 7); and 2) synthesis of this protein is 
defective in C3H mice. 
Northern blot analysis of C3H and C57 liver RNA using 
a rID~I cDNA~probe revealed a strong hybridization signal 
with RNA of 2.1 kilobases, i.e. the same size as rID-I mRNA 
(6). This suggests a high degree of homology between rat 
and mouse ill-I, which has also been found between the 
sequences of human and rat ID~I (6, 7). Differences in ID~I 
activity in both C3H and C57 mice are closely paralleled by 
variation in liver ID~I mRNA, and the mean ID~I mRNA 
level is significantly lower in C3H than in C57 mice. This is 
true irrespective of whether ID~I mRNA is expressed in 
absolute terms or relative to ,B-actin mRNA. However, since 
it is unkno'Wll. if .B~actin gene expression is the same in C3H 
and CS7 mouse livers, it is questionable if the ID~I!.B-actin 
mRNA ratio is an appropriate means to standardize the 
results. Our fmdings indicate that ID~l activity is impaired in 
C3H mice because of decreased transcription of the ID-I gene 
or decreased stability of the mRNA. OH mice show a· high 
prevalence of spontaneous liver tumor formation (19), and 
reduced expression of ID~I may thus reflect dedifferentiation 
of preneoplastic liver cells. However, heterozygosy for an 
ID~I gene defect in C3H/He mice cannot be excluded en-
tirely. It is unlikely that reduced hepatic T3 formation has a 
role in hepatocarcinogenesis, since this is not a general con-
sequence of hypothyroidism. 
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The type III iodothyrorune deiodinase (ID-IlI) catalyzes the inner ring dciodination and, thus. the inactivation of the thyroid hormones T4 and 
T).lD·III activity in rat brain. rat placenta and embryonic chicken liver is inhibited by the nffiruty label N.bromoacetyi.T) (BrAcT)) with an affinity 
similar to that of T). Reaction of rat brain and placenta microsomes with BrAcr~l1T) resulted in the extensive labeling of a 32 kDa protein (p32). 
However. p32 was also prominently labeled in fetal rat liver nricrosomes which have no m·m activity. Labeling of p32 was not influenced by 
loo,uM substrate :maIogs or inhibitors of ID~III. some of which completely inhibit ID-III activity at 1 ,uM. BrAce::!lI]T) labeling of o::mbryonic 
chicken liver microsomes did not reve:ll p32 or another protein possibly related to IO-Ill. In contrast to previous suggestions. it is unlikely that 
p32 represents IO-III or a subunit thereof. 
Thyroid honnone: Iodothyronin~ Oeiodination: Rat: Chicken; Liver: Placenta; Brain; Affinity-labelling; Bromoaeetyl derivative 
1. INTRODUCTION 
The thyroid predominantly secretes the inactive pro-
honnone thyroxine (T4). Therefore. extrathyroidal 
outer ring deiodination to bioactive 3.3'.5-triiodothy-
ronine (TJ) is an essential step in the exertion of thyroid 
honnone action. Alternatively. T4 is converted by inner 
ring deiodination to the inactive metabolite 3.3' S -triio-
dothyronine (reverse T j • rTJ). Inner ring deiodination 
also inactivates T J by converting it to 3.3'-diiodothyron-
ine (3.3'-T 0 [1.2]. 
Three types of iodothyronine deiodinases have been 
identified in mammals. The type I deiodinase (ID-I) is 
capable of both inner and outer ring deiodination and 
is responsible for the greater part of peripheral T 3 pro-
duction from T4. However. the preferred substrate of 
the enzyme is rTJ• The enzyme is located in the micro-
somal fractions of liver. kidney and thyroid [1.2]. The 
iodothyromne derivative N-bromoacetyl-TJ (BrAcT,) 
has proved to be a very useful affinity-label for ID-I, 
resulting in the identification of the "., 27 kDa ID-I 
protein by SDS-PAGE [3-5]. Human. rat and mouse 
ID-I have been shown to contain the rare amino acid 
selenocysteine [6-8]. 
The type 111 iodothyronine deiodinase (ID-I1I) is the 
least well described deiodinase. It catalyzes the inactiva-
tion of thyroid hormone by inner ring deiodination of 
T4 and TJ [1.2]. In mammals. ID-III is mainly located 
·Corresponding author. Fax: (31) (10) 463-54.30. 
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in the microsomal fractions of brain [9J. placenta [10]. 
skin [11] and fetal intestine [12]. In chicken liver, the 
enzyme is mainly present during embryonic develop-
ment. with the highest activity on day 16 and decreasing 
rapidly thereafter until very low levels are reached at 
hatching on day 21 [13]. In this study we tested if 
BrAcT) is a useful affi.nity~label for ID-III in rats and 
chickens. 
2. MATERIALS AND METHODS 
2.1. Materials 
[3.5_ 1Z,1]T) ( ... 30 Cilmmol) was generously provided by Drs. C. 
Horst and R. Thoma. Henning (Berlin, Germany); [3'S-mIJrT) and 
{3'_'Z,1]T, ("" 1700 Cilmmol) were obta.ined from Amershrun (Amer-
sham, UK); thyronine (To) and iodothyronines from Henning; dithio-
threitol (Dm, 6-n-propyl-2-thiourncil (PTU). 3.3'.5-triiodothy-
roacetic acid (Triac) and 3.5-diiodotyrosine (DIT) from Sigma (St. 
Louis. MO): iopanoic acid (roP) from Sterling Winthrop (Newcastle, 
UK): electrophoresis grade SDS-PAGE reagents from Bio-Rad 
(Richmond. IL); BCA Protein Assay Reagent from Pierce Europe 
(Oud Bei.jerland. The Netherlands); M, markers and Sephadex LH-20 
from Phannacia CtJppsala. Sweden); and Coomassie brilliant blue 
R-ZSO from Merck (Darmstadt. FRG). 
2.2. Preparation of mU:rO$omes 
WlStt\r rats werc purch3.sed from Harlan Sprague-Dawley (Zeist. 
The Netherlands), LiVer and brain were isolated from 10-wcck-old 
male rats after decapitation. Pregnant rats and fetuses were sacrificed 
on day 20 of gestation. and the placentas. fetal livers and brains were 
isolated. Fenilize<i chicken eggs were obtained from a I~ supplier 
and incubated for 14, 16, 18 or 20 days in a forced-draughtincubator 
at 37"C and 80% humidity, Eggs were opened. the embryos were 
decapitated. and the livers were isolated. All tissues were immediately 
t'rOlen in liquid nitrogen and stored at -70°C until further use. Micro-
Reaction of type III deiodinase with BrAcT3 
somes were prepared in buffer A (10 roM Tris--HQ (pH 7.4), 3 mM 
EDTA and 3 mM DTr) as previously described [14] and stored at 
-70Q C. Protein content wns measured by Pierce SCA protein assay, 
using bovine serum albumin as the standard. 
2.3. Affinil.~/abe'ing 
BrAce~IJTJ and non-radioactive BrAcT, were prepared essentially 
llS previously published [3J. HPLC analysis demonstrated that the 
purity of BrACe::SI]T, was ~ 85%. with unreacted [IZI'JT, as the main 
contaminant, while non-radioactive BrAcT) was > 95% pure. Solu-
tions of BrAc['~I]T, a.nd BrAcT, in ethanol were pipettoo into an 
Eppendorf tube, and the solvent was evaporated at 42"C under a 
stream of nitrogen. The desired ::unount of microsomal protein in 100 
,ul butTer A was added to the residue. and the mixture was vonexed 
for 30 s, After further incubation for 10 min at 37°C. labeling was 
stopped by addition of 50 ,ul of 80S-sample butTer cont:l.ining 30% 
,B-mercaptoethanol and treatment for 5 min at IOOQC. Proteins were 
:;epatated overnight by SOS-PAGE in a 14 em 10% or 15% T, 3% C 
gel, overlaid by a 2 em 3% T, 3% C stacking gel [IS]. Gels were stained 
with Coomassie brilliant blue R·2S0, dried under vacuum and autora-
diographed at -70°C with Kodak T·mat G film. M, was determined 
by interpolation with protein markers. 
2.4. Dl!iodinase assays 
The activity ofIn-! was measured by incubation of 10 ~gJr:nJ micro-
somal protein for 20 min at 37'C with I ).1M rT) and 75 nCi 
[3',5'·mIJrT, in 200.u1 0.2 M phosphate (pH 7.2), 4 mM EOTA and 
5 mM OIT. followed by isolation of the '~I' released on Sephadex 
LH·20 as previously described [16). 
The activity of ID-III was measured by incubation of different 
amounts of microsomal protein for 60 min at 37'C with I nM [I~I]T) 
in 200 ~I 0.2 M phosphate (pH 7.2). 4 mM EOTA and.20 roM DIT. 
Both inner and outer ring labeled [':::II)T, were used. yielding identical 
results. When [3'.I:::1I]T) was used, the reactions were StOPped byaddi-
tion of 300).11 methanol on ice. After centrifugation, the supernatants 
were analyzed for [3,3,-':::II]T: formation by HPLC on a 100 x 3.0 mm 
Chromspher C'8 column (Chrompack, Middelburg, The Nether-
lands), duted with a 45:.55 (v/v) mixture of mctl1anol and 20 mM 
:unmonium acetate {pH 4.0) ata flow of 0.8 mVntin. When [3.5. I:::II]T) 
was used. reactions were stopped by addition of 100).11 pooled human 
serum on ice. followed by precipitation of protein.bound iodothyron-
incs by addition of 500 ~I 10% trichloroacetic acid. Mter centrifuga-
tion, the supernatants were analyzed for I!:II- formation on Sephadex 
LH-20. Parallel incubations were done with 1 ~M T). which saturates 
the low-K", In-III but not the high.K... ID·I [l.2J. showing negligible 
type I or non-enzymatic deiodination ofT). 
3. RESULTS 
In the rat, high IO-ITI aCUvltJ.es are found in the 
microsomal fraction of placenta and brain, while the 
enzyme is more abundant in brain of fetal than of adult 
rats. After reaction of rat placenta and brain micro-
somes with BrAc[I2SI]T3 and subsequent analysis by 
SOS-PAGE, a predominant radioactive band of 32 kDa 
(p32) was observed. with higher levels in fetal than in 
adult rat brain (Fig. 1). In none of these microsomes 
significant ID-I activity was found, which was associ-
ated with the absence of a 27 kDa band (p27). represent· 
ing BrAcT)-labeled ID-I. in the corresponding autora-
diograms, 
Both fetal and adult rat liver microsomes showed 
little IO-UI activity. However. reaction of fetal liver 
microsomes with BrAc['2SI]T3 resulted in extensive la-
beling ofp32 (Fig. 2A). This is quite different from adult 
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Fig. l. Labeling patterns obtained-after reaction of 50 ~g of micro-
somal protein with 0.15).1ei BrAc[l:::lI]T). Mter SOS-PAGE film was 
exposed. for 4 days. (A) Rat pi:l.ccnta, (B) Adult rat brain. (C) Fetal 
rat brain. 
rat liver microsomes, where labeling of p32 is nearly 
absent (Fig. 2B). In contrast with fetal liver. micro-
somes of adult rat liver contain high levels of ID~I activ-
ity, leading to extensive labeling of p27. which could 
interfere with labeling of p32. However. inhibition of 
p27 labeling by addition of rT3 and PTU resulted in 
only a minor increase in p32 labeling (Fig. 2C). Under 
these circumstances an increase was also observed in the 
labeling of a 56 kDa band, identified previously as pro-
tein disulfide isomerase [4], and of a 67 kDa band. These 
findings indicate that the level of p32 in adult rat liver 
microsomes is very low. 
In spite of the discrepancies found between ID~III 
activity and p32 labeling, we further investigated their 
possible relationship by analyzing the effects of sub~ 
strates and inhibitors of the enzyme on BrAcT31abeling 
of p32. Therefore. rat brain microsomes were reacted 
with BrAc[I2SIJT 3 in the presence of 100 ,uM of various 
substrate analogs and deiodinase inhibitors. Labeling of 
the microsomal proteins was not influenced by any of 
the substances tested (Fig. 3A). However. deiodination 
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Fig. 2. Labeling patterns obtained after reaction of 50 pg or micro-
somal protein with 0.15 ,uCi BrAc('~IJT). After SOS·PAGE film was. 
exposed for 4 days. (A) Fetal rat liver. (8) Adult rat liver. (C) AdulL 
rat liver in the presence of 10 JiM tTl and 100,uM PTU. 
of ["'I]T, by ID-III was largely inhibited by I I'M T,. 
T4• Triac or lOP (Fig. 3B). 
In embryonic chicken liver, highest ID-III activity 
was observed at or around day 16 of embryonic devel~ 
opment (El6); thereafter. ID-III activity decreases rap-
idly to become nearly undetectable in adult chicken liver 
microsomes (Fig. 4A): see also [13]). Reaction of embry~ 
onie and adult chicken liver microsomes with 
BrAc[I25I]T3 did not reveal labeling of p32 or any other 
protein possibly correlated with ID-III activity (Fig. 
4B). In adult chicken liver microsomes ID-I has been 
identified as a 26 kDa band [16]. Figure 4 shows the 
strong correlation between affinity labeling of this 26 
kDa band and the varying ID~I activity in chicken liver 
during embryonic development. 
ID~III activity of chicken E16liver microsomes and 
rat placenta microsomes was measurf:d. in the presence 
of increasing concentrations of BrAcT3 or T3 (Fig. 5). 
In both tissues. deiodination of [1:!5I]T3 was inhibited by 
similar concentrations ofT, and BrAcT,. with IeS<l val~ 
.ues varying between 5.7 and 8.1 nM. After preincuba~ 
tion of rat placenta or E16 chicken liver microsomes 
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with T, or BrAcT,. time-dependent inactivation ofID~ 
III was observed with BrAcT,. but not with TJ• which 
persisted after removal of unreacted BrAcT, by Pen-
efsky centrifugal column chromatography [17] (results 
not shown). These findings suggest the covalent modifi~ 
cation of rat and chicken ID~III by BrAcT,. 
4. DISCUSSION 
The low apparent Km. ofT, (- 5 nM) for both rat and 
chicken ID-III estimated in the present study is in agree-
ment with previously published data [19.20]. We also 
found that. although ID-III is irreversibly inactivated 
by BrAcT,. the apparent K, of this compound is similar 
to the K.n of the substrate T ,. This is quite different from 
inhibition of ID~I by BrAcT3' which is half-maximum 
at - 0.1 nM of the inhibitor. a concentration much 
lower than the K.n for T3 (6,uM) or even rT3 (0.06,uM) 
[3]. This is most likely caused by reaction of BrAcT, 
with the highly reactive selenocysteine residue in ID-1. 
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Fig. 3. (A) l.:lbeling patterns obtained after reaction of 66 f./.g of rat 
brain microsomal protein with 0.1 jJCi BrAc['~IJT) in the absence or 
presence of 100 jJM of various substrate analogs. and dciodinase inhlb-
itors. After SDS-PAGE film was exposed for 42 h. (B) Dciodination 
of 1 nM ['~IJT) by $00 jJf!/rnl rat brain microsomal protein in the 
absence or presence of 1 jJM of the compounds ind.ic:lted. except that 
PTU was ad.ded at 100 jJM. Activities are expressed as a percentage 
of that in the absence of the various additions. 
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The difference in sensitivity to inactivation by BrAcT 3 
between 10-1 and ID·IIT may be explained by the find-
ing that ID-III is apparently not a selenoenzyme [211. 
Santini et ai. have recently reported similar findings 
concerning the inhibition afID-III activity as well as the 
labeling ofa 31 kDa protein with BrAcT) in rat placen-
tal microsomes [18]. They suggested that this 31 kDa 
protein is the substrate-binding subunit of ID-III. al-
though its labeling was only partially inhibited in the 
presence of as high as 150 pM T 3' while it was also 
observed in tissues with no ID-III activity. However, we 
have serious doubts about the relationship between p32 
and ID-III. Firstly, BrAcT) labeling of p32 is observed 
not only in tissues with high ID-III activity (rat·brain 
and placenta) but also in tissues with little or no enzyme 
activity (fetal rat liver and adult rat spleen) [22}. Sec-
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\ '~'T3 g 
\,\ - 8,"T3 
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~ 
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ondly, BrAcT) labeling ofp32 is not observed in embry-
onic chicken liver. which shows very similar levels and 
properties of ID-III activity as rat placenta., and which 
is as sensitive to BrAcT) inhibition as rat ID-III. 
Thirdly. BrAcT) labeling of p32 is not inhibited in the 
presence of 100.uM T3• which is > I04_fold higher than 
its apparent K.n and. thus. should completely block 
modification of the substrate-binding site by BrAcT3' 
which has a similar affinity for the enzyme as T). There-
fore, our findings do not support the hypothesis that 
p32 is a subunit of ID-III. 
Although ID-III is irreversibly inactivated by 
BrAcT3. we were not able to identify the enzyme by 
affinity-labeling with this compound. which could be 
explained if: (1) BrAc[lzsI]T3 is degraded after coupling 
to ID-III. leading to loss of radioactivity: (2) the 
"0 
\ =::"" g 80 ;:-~ 
'0 60 
0 
" 
,. ~-. '" 20 
8 7 
B - 109[M] 
Fig. 5. Deiodination of 1 nM e~l]T, by chicken E16liver microsomes (A; 20 jJ.g protein/ml) or rat placenta microsomes (B; 25 jJ.g protein/mI) in 
the presence of increasing concentr:l.oons of BrAcT). Results are expressed as a percentage of that without additions. 
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amount of ID~III present in the various microsomes is 
too low to allow sufficient incorporation of 
BrAce2SI]T3; or (3) the Me of ID-III is close to that of 
another prominently labeled protein. interfering with 
the detection of labeled ID-Ill. 
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AFFINITY -LABELING OF IODOTHYRONINE DEIODINASES IN RAT 
TISSUES WITH N-BROMOACETYL-IODOTHYRONINE DERIVATIVES 
Christian H.H. Schoenmakers, Ingrid G .A.J. Pigmans and Theo J. Visser 
Department of Internal Medicine ill, Erasmus University Medical School, 
Rotterdam, The Netherlands 
SUMMARY: In the present study the hypothesis was tested that N-bromoacctyl-3,3',5-
[l25Iltriiodothyronine (BrAc[ 125I1T3) is a useful affinity label for both type I and type III 
iodothyronine deiodinases (ID-I and ID-III). Therefore, the microsomal fractions of various rat tissues 
Were tested for JD-I and ID-ill activities, and microsomal proteins were labeled with BrAc[125I]T3 
and analyzed by 5DS-PAGE. In agreement with previous observations, high ID-I activities were found 
in liver, kidney and t~roid, and high ID-III activities in brain, in particular fetal braiIL, and placenta. 
5DS-PAGE of BrAc[ 25I]T3-labeled microsomcs showed a prominent radioactive ::::::27 kDa protein 
(p27) in liver, kidney and thyroid, which was previously identified as ID-I, and a :=::::32 kDa protein 
(P32) in brain, in particular fetal brain, and placenta. A good correlation was found between the 
affinity-labeling of p32 and the inactivation of ID-III by BrAcTI, suggesting that p32 represents ID-III 
or a subunit thereof. After treatment of microsomes with 0.05% deoxycholate or carbonate buffer 
(pH 11.5) p32 was still labeled by BrAc[125I]T3, indicating that p32 is a transmembrane protein. 
Altho~3,3,,5'-triiodothyronine (rD) is not a substrate for ID-III, ~2 was readily labeled with 
BrAc[ I]rTI. Labeling of p32 in rat brain microsomes by BrAc[1 I]rn was not affected by 
addition of lOO.uM unlabeled thyroxine (T4) or TI, whereas deiodination of [l25I]T3 by ID-III was 
inhibited by 91 and 96 % in the presence of 1.uM T4 and T3, respectivel1. The relationship between 
p32 and ID-III was further questioned by findings of prominent BrAc[ 25I]TI labeling of p32 in 
microsomes of spleen and fetal liver, which show very little ID-III activity. Peptide-mapping of p32 
using trypsin or Staphylococcus aureus V8 protease yielded the same fragments in brain, placenta. 
spleen and fetal liver, suggesting that p32 is identical in all these tissues. In contrast to initial 
suggestions, therefore, we conclude that it is unlikely that the labeling of p32 by BrAc[125I]T3 
represents the identification of ID-Ill. 
INTRODUCTION 
Differentiation, growth and basal 
metabolism are regulated by thyroid 
hormones, of which 3,3' ,5-triiodothyronine 
(T3) is the most bioactive form (1,2). The 
actions of T3 are initiated by its binding to 
nuclear receptors, which are encoded by 
the c-erbA a and B genes, resulting in the 
stimulation or suppression of the 
transcription of thyroid hormone responsive 
genes (1,2). The thyroid predominantly 
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secretes the biologically inactive 
prohormone thyroxine (T4), which is 
activated by outer ring deiodination (ORD) 
to T3. Alternatively, T4 undergoes inner 
ring deiodination (rRD) to the biologically 
inactive metabolite 3,3' ,5'-triiodothyronine 
(reverse T3, rT3). Both ORD and IRD are 
catalyzed by so-called iodothyronine 
deiodinases (3,4). 
Until now three different types of 
iodothyronine deiodinases have been 
identified. Type I iodothyronine deiodinase 
Labeling of deiodinases with BrAc-iodothyronine derivatives 
(ID-I) in mammals is found predominantly 
in the microsomal fractions of liver, kidney 
and thyroid, and is responsible for the 
largest part of peripheral production of T3 
from T4. However, ID-I is capable of both 
ORD and IRD, and shows preference for 
rT3 as the substrate (3,4). ID-I is 
stimulated by small thiol compounds such 
as dithiothreitol (DTT) and is inhibited by 
6-n-propyl-2-thiouracil (PTU) in an 
uncompetitive manner (3,4). N-Bromo-
acetyl-[ 12SI]T3 (BrAc[ 125I]T3) has proven 
to be a very useful affinity-label of ID-I, 
allowing the specific identification of the 
enzyme in liver micro somes despite that it 
only constitutes =0.01%· of the total 
protein (S,6). 
We have previously shown that liver ID-I 
displays very similar structural and 
enzymatic properties in different species, 
except for the lesser substrate preference of 
dog ID-I for rT3 (7). The complete 
nucleotide sequences of rat, human and dog 
ID-I cDNA have been reported (8-10), 
showing a high degree of homology 
between these proteins, including the 
presence of the rare aminoacid 
sclenocysteine (Sec). Mouse ID-I has also 
been shown to be a selenoprotein (11,12). 
In rats, the selenium (Se) status greatly 
influences the amount of ID-I in liver, 
kidncy and thyroid, with ID-I activity being 
markedly decreased in Se-deficient animals 
(13,14). 
Type II iodothyronine deiodinase (ID-I1) 
in mammals is mainly found in the 
microsomal fractions of brain, brown 
adipose tissue and pituitary (3,4). It 
catalyzes only the ORD of iodothyronines, 
with T4 as the preferred substrate. !D-ll is 
important for the local production of T3 
from T4 to maintain the intracellular levels 
of this active hormone in critical tissues 
such as the brain (3,4). ID-I1 is also 
stimulated by small thiol compounds such 
as DIT, but it is insensitive to inhibition 
by PTU (3,4). 
The type III iodothyronine deiodinase 
(ID-III) in mammals is mainly located in 
the microsomal fractions of brain (IS), 
placenta (16), skin (17) and fetal intestine 
(18). This enzyme catalyzes the IRD and, 
thus, the inactivation of T4 and T3, the 
latter being the preferred substrate (3,4). It 
has recently been found that ID-III is 
readily inactivated b~ BrAcTI (19), 
suggesting that BrAc[ 1 SI]TI may be an 
useful affinity-label for the identification of 
ID-Ill. 
In this study, we compared the 
distributions of ID-I and ID-III in different 
rat tissues with the labeling patterns 
obtained after reaction of subcellular 
fractions of these tissues with N~bromo­
acetyl-[ 12SI]iodothyroninederivatives. This 
was done to investigate if ID-lII can be 
identified using such affinity-labels. 
MATERIALS AND METHODS 
Materials. 
[3' ,S,_12SljrT3 and [3,_12Si]TI (= 1700 
Ci/mmol) were obtained from Amersham 
(Amersham, UK); unlabeled iodothyronines 
from Henning (Berlin, Germany); sequence 
grade trypsin and Staphylococcus aureus 
V8 protease from Boehringer Mannheim 
(Mannheim, Germany); DTT, sodium 
deoxycholate (DOC) and PTU from Sigma 
(St. Louis, MO); electrophoresis grade 
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SDS-P AGE reagents from Bio-Rad 
(Richmond, IL); BCA Protein Assay 
Reagent from Pierce Europe (Oud 
Beijerland, The Netherlands); protein 
markers and Sephadex LH-20 from 
Pharmacia (Uppsala, Sweden); and 
Coomassie Brilliant Blue R-250 from 
Merck (Darmstadt, Germany). 
Preparation of microsomes. 
Wistar rats were purchased from Harlan 
Sprague Dawley (Zeist, The Netherlands). 
Tissues were isolated from lO-week old 
male rats killed by decapitation. In 
addition, placenta and fetal liver were 
obtained from pregnant rats on day 20 of 
gestation. Immediately after isolation, all 
tissues were frozen in liquid nitrogen and 
stored at -70 C until further use. 
Microsomes were prepared as previously 
described (20) by homogenization of the 
tissue in 0.25 M sucrose, 10 mM HEPES 
(PH 7) and 10 mM DTT, and successive 
centrifugation for 10 min at 25,000xg and 
for 60 min at 100,000xg. The supernatants 
and pellets of these centrifugation steps 
were designated S25, P25, S100 and Pl00 
(micro somes) , respectively. The 
microsomes were suspended in 10 mM 
Tris/HCl (PH 7.4), 3 mM EDTA and 3 
mM DTT (buffer A), and aliquots thereof 
as well as of the other fractions were stored 
at -70 C until further analysis. Protein 
content was measured by Pierce BCA 
protein assay using bovine serum albumin 
as the standard. Treatment of microsomes 
with deoxycholate (DOC) or high pH was 
done as follows. Microsomes were 
suspended in 10 ml 0.1 M sodium 
carbonate (PH 11.5) or in 25 mM HEPES 
80 
(pH 7.4),0.25 M sucrose and 50 mM KCl 
with or without 0.05% DOC. After 
occasional stirring on ice for 1 h, the 
mixtures were layered on 2 ml 50 mM 
HEPES (PH 7.4), 0.5 M sucrose, 50 mM 
KCl and 2 mM DTT, and centrifuged for 
90 min at 105,000xg and 4 C. The 
resulting pellets were resuspended in 1 m! 
of buffer A, and stored in aliquots at -70 C 
until further examination. 
Affinity-labeling. 
Labeled and unlabeled BrAc-
iodothyronine derivatives were prepared 
essentially as previously published (5,6). 
HPLC analysis demonstrated that the purity 
of BrAc-[ 125Ijiodothyronines was at least 
85% with unreacted [125Ijiodothyronines 
as the main contaminant, while nonradio-
active BrAc-iodothyronines were more than 
95% pure. Ethanol solutions containing the 
desired amounts of BrAc-iodothyronine and 
BrAc-[ 125Ijiodothyronine were pipetted in 
an Eppendorf tube, and the solvent was 
evaporated under a stream of nitrogen at 42 
C. The required amount of microsomal 
protein in 100 1'1 buffer A was added to the 
residue, and the mixture was vortexed for 
30 s. After further incubation for 10 min at 
37 C labeling was stopped by addition of 
501'1 of SDS-sample buffer containing 30% 
,B-mercaptoethanol and treatment for 5 min 
at 100 C. Proteins were separated overnight 
by SDS-PAGE in a 14 cm 15% T, 3% C 
gel, overlaid by a 2 cm 3% T, 3% C 
stacking gel (21), where T denotes the total 
concentration (wt/vol) of both monomers 
(acrylamide and bisacrylamide) and C 
denotes the concentration of bisacrylamide 
relative to the total concentration T. Gels 
Labeling of deiodinases with BrAc-iodothyronine derivatives 
were stained with Coomassie Brilliant Blue 
R-250 at 60 C, dried at 60 C under vacuum 
and autoradiographed at -70 C with Kodak 
T-MAT G film. Apparent molecular mass 
(Mr) was determined by interpolation with 
protein markers. The correlation between 
the labeling of microsomal proteins and the 
inactivation of ID-III by BrAcT3 was 
examined as follows. 400 I'g rat brain 
microsomal protein in 200 1'1 0.1 M 
phosphate (PH 7.2), 4 mM EDTA and 20 
mM DTT was reacted with 30 pmol 
BrAc[ 125I]T3 for increasing time periods. 
Unreacted BrAc[ 125I]T3 was subsequently 
removed by Penefsky centrifugal column 
chromatography (22). Control experiments 
revealed that in this way more than 99.9 
percent of unreacted affinity-label was 
removed. The affinity-labeled microsomes 
were subsequently analyzed by SDS-PAGE 
and tested for ID-III activity. 
Peptide mapping. 
The desired amount of labeled 
microsomal protein was separated overnight 
by routine SDS-PAGE. Gels were stained 
for 5 min with Coomassie Brilliant Blue 
R-250 at room temperature. After 
destaining, lanes were excised from the gel 
and cut into 1 mm fractions, which were 
counted for radioactivity. Fractions 
containing the protein of interest were 
further analyzed as previously described 
(23). Using 11'g of protease per 200l'g 
starting protein, digestion was done in a 
tricine-SDS-polyacrylamide gel running at 
30 V constant (24). This gel was composed 
of a 12 em 16.5% T, 3% C small-pore gel 
overlaid by a 2 cm 10% T, 3% C spacer 
gel, that again was overlaid by a 2 cm 
4% T, 3% C stacking gel. Autoradiograms 
were prepared and Mr was determined as 
described above. 
JD-I assay. 
The activity of ID-I was measured by 
incubation of 2 p,g microsomal protein for 
30 min at 37 C with 0.1 I'M rT3 and 75 
nCi [125I]rT3 in 200 1'1 0.2 M phosphate 
(PH 7.2), 4 mM EDTA and 5 mM DTT as 
previously described (7). The reactions 
were stopped by addition of 750 1'1 1 M 
HCI on ice. The 125r released was 
isolated on Sephadex LH-20 and data were 
corrected for non-enzymatic deiodination 
determined in incubations without 
microsomes. Random labeling and 
deiodination of the 3' and 5' positions of 
[125I]rT3 was taken into account for 
calculation of ID-I activity. 
JD-III assay. 
The activity of ID-III was measured by 
incubation of 20 or 200 I'g microsomal 
protein for 60 min at 37 C with 1 nM T3 
and 75 nCi [3,_I25I]T3 in 200 1'1 0.1 M 
phosphate (pH 7.2), 4 mM EDTA and 10 
mM DTT. The reactions were stopped by 
addition of 300 1'1 methanol on ice. After 
centrifugation of precipitated proteins, the 
supernatants were analyzed for 3,[3'-
125I]T2 formation by HPLC on a 100 x 
3.0 mm Chromspher C18 column 
(Chrompack, Middelburg, The 
Netherlands), eluted with a 45:55 (vol/vol) 
mixture of methanol and 20 mM 
ammonium-acetate (pH 4.0) at a flow of 
0.8 ml/min. Control incubations were done 
with 1 I'M T3, which saturates the low-Km 
ID-III but not the high-Km ID-I (3,4), 
showing negligible type I or non-enzymatic 
deiodination of T3. 
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Reproducibility. 
The data shown were obtained in 
representative experiments that were 
repeated 2 or 3 times with closely agreeing 
results. 
RESULTS 
Figure 1 shows the ID-I activities 
determined in the microsomal fractions of 
the various rat tissues. It is clear that 
kidney, liver and thyroid microsomes 
contained high ID-I levels, whereas 
pancreas, spleen, small bowel, large bowel, 
lung, muscle, brain, placenta and fetal liver 
displayed very low activities. The ID-III 
activities of these same microsomal 
preparations are depicted in Fig. lB. Brain 
and placenta microsomes exhibited high ID-
III activities, in fetal brain higher than in 
adult brain, whereas the other tissues 
showed almost no activity. An 
autoradiogram of the SDS-PAGE separation 
of proteins labeled by reaction of the 
various microsomes with BrAc[ 1251]T3 is 
presented in Fig. 1C. The film was 
overexposed in order to also reveal weakly 
labeled proteins. This is indicated by the 
very intense band at =27 kDa (p27) in 
Fig. 1. (A) Tissue distribution of type I dciodinase 
activity in rat. ID~I was assayed using 0.1 pM [1'3 
and 10 ,ug/ml microsomal protein. (B) Tissue 
distribution of type III dciodinasc activity in rat. !D-
III was assayed using 1 nM T3 and 100 pg/mJ. 
microsomal protcin.(C) Autoradiogram of labcling 
patterns obtained after rcaction of 50 pg microsomal 
protein of rat tissue with 0.15 pCi BrAe[l25I]T3. 
After SDS~PAGE film was exposed for 19 h. 
Mu, muscle; He, heart; Lu, lung; LB, large bowel; 
SB, small bowel: Sp, spleen; Pa, pancrcas; Li, 
liver; Ki, kidney; Th, thyroid: Br, brain: FB, fetal 
brain; FL, fetal liver: PI, placenta. 
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Fig. 2. (A) Autoradiogram of labeling patterns obtained after reaction of 30 pmal BrAc[l25I]T3 with 400 p.g 
rat brain microsomal protein for increasing time periods. Reaction time is given in minutes above each lane. 
After SDS~PAGE film was exposed for 7 days. (B) Remaining ID-III activity of the same microsomal samples 
shown in A. ID-Ill was assayed using 1 nM 1'3 and 1 mgfml microsomal protein. 
liver, kidney and thyroid microsomes. 
These are also the tissues with high ID-I 
activity, and p27 has previously been 
identified as ID-I (6). In the tissues with 
high ID-III activities, i.e. brain and 
placenta, a prominent BrAc[ 125IjT3_ 
labeled protein of =32 kDa (P32) was 
observed, which was more pronounced in 
fetal brain than in adult brain. However, 
BrAc[ 125IjT3-labeling of p32 was also 
observed in spleen and fetal liver 
microsomes, which contained little or no 
ID-III activity. 
In order to investigate if p32 represents 
the labeling of ID-III, the correlation was 
examined between the extent of p32 
labeling and that of ID-III inactivation after 
reaction of rat brain microsomes for 
increasing time periods with BrAc[ 125IjT3 
followed by removal of unreacted label. 
The results of these experiments are 
presented in Fig. 2, which demonstrates 
that there was indeed a close correlation 
between the time~dependent increase in p32 
labeling and the decrease in ID-III activity. 
A similar relationship between p32 labeling 
and ID-III inactivation was found in 
experiments where the reaction time was 
ke~t constant but the amount of BrAc-
[125IjT3 was varied (results not shown). 
Rat brain, placenta, spleen, and liver 
microsomes were treated with 0.05% DOC 
in order to remove lumenal proteins (25) or 
with carbonate buffer of pH 11.5 that 
detaches all but the very tightly bound 
transmembrane proteins (26), and the thus 
treated microsomes were labeled with 
BrAc[ 125IjT3 . Figure 3 shows that 
pretreatment of rat liver microsomes with 
0.05% DOC resulted in the disappcarance 
of the 56 kDa band, which has previously 
been identified as the soluble lumenal 
enzyme protein disulfide isomerase (POI). 
Pretreatment with carbonate buffer of 
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Fig. 3. Influence of pretreatment of [at brain. 
placenta, spleen and liver microsomcs with 
0.05% DOC or with carbonate buffer of pH 11.5 on 
labeling of proteins with BrAc[ 125I]'I3. Microsomes 
were processed as described under Materials and 
Methods. Of the resulting suspensions 15 pg protein 
was reacted with 0.25 pei BrAc[ 125I]1'3. After 
SDS-PAGE film was exposed for 22 h. 
pH 11.5 resulted in the elimination of p27 
labeling. Control experiments in which 
reaction with BrAc[ 125I]T3 preceded 
treatment with carbonate buffer of pH 11.5 
revealed that this is caused by the 
inactivation of ID-I rather than the removal 
of this enzyme from the micro somes, 
confirming that ID-l is a tightly bound 
transmembrane protein. Reaction of 
BrAc[ 125I]T3 with brain, placenta and 
spleen microsomes after treatment with 
0.05% DOC or pH 11.5 still resulted in the 
labeling of p32, indicating that p32 is a 
transmembrane protein. The strong 
association of p32 with the microsomal 
membranes was also demonstrated by the 
complete lack of p32 labeling in the final 
supernatant (SI00) of the spleen homo-
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p56 
po2 
Fig. 4. Autoradiogram of labelin~15tterns obtained 
after reaction of 0.25 pei BrAc[ I]T3 with 100 
pg protein of different fractions of spleen tissuc~ 
homogenate obtained during preparation of 
microsomes using differential centrifugation. After 
SDS~PAGE film was exposed for 18h. TOT. total 
homogenate; 25S, 25,OOOxg supernatant; 25P, 
25,OOOxg pellet; 100S, 100,000xg supernatant; 
lOOP, 100,OOOxg pellet. 
genate obtained after centrifugation of the 
microsomes (PI GO; Fig. 4). Figure 4 also 
shows significant BrAc[ 1251]T3 labeling of 
p32 in the low-speed pellet (P25) of spleen 
homogenate. A similar distribution of p32 
over the different tissue fractions was seen 
in placenta, brain and fetal liver (not 
shown), but the exact subcellular location 
of this protein has not been further 
investigated. 
If labeling of p32 by BrAc[I25I]T3 
represents the covalent binding of the 
affinity-label to the substrate-binding site of 
ID-lII, this labeling should be inhibited in 
the presence of substrates of the enzyme, as 
is the case with the BrAc[ 1251]T3 labeling 
of ID-l (6). Furthermore, one would not 
expect to observe labeling of p32 with a 
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43_ 
.... ",-p32 30- ,-,'- - ~: - ,_, - __ 
20-
14-
A B c o 
Fig. 5. Autoradiogram of labeling patterns obtained 
after reaction of 100 fig of ry,laccnta microsomal 
protein with O.25,uCi BrAc[ 1 I]rT3 in the absence 
(A) or presence of 100 I'M T4 (B), 100 I'M T3 (e) 
or 100 I'M T3 + 100 I'M PTU (D). Mter SDS-
PAGE film was exposed for 4 h. 
BrAe-derivative of a iodothyronine such as 
rT3 which is not a substrate for ID-III. 
Therefore, rat brain microsomes were 
reacted with BrAc[ 125IlrT3 in the absence 
or presence of excess unlabeled T4 or T3. 
Figure 5 shows that the labeling of p32 
with BrAc[ 125IlrT3 was as effective as the 
labeling of this protein with BrAc[ 125I1T3 . 
Moreover, labeling of p32 by 
BrAc[ 125I1rT3 was not affected by addition 
of 100 I'M T4 or T3 either in the absence 
or the presence of 100 I'M PTU. However, 
deiodination of [125I]T3 by ID-III was 
inhibited for 91 and 96 % by 1 I'M T4 and 
T3, respectively. These findings are in 
agreement with previous observations that 
p32 labeling in rat brain microsomes by 
BrAc[ 125I1T3 is not affected in the 
control VB 
Br PI FL Sp Br PI FL Sp 
kDo 
30 _ .- .. • .; jf, - p32 
18 -
14 -
6.4 -
3.4 - ••••• 
Fig. 6. Autoradiogram of labeling patterns obtained 
after peptide-mapping of p32 originating from brain, 
placenta, fetal liver and spleen. After reaction of 
200 Pj microsomal protein with 2.5 p.Ci 
BrAct 251]1'3 and subsequent SDS~PAGE, p32 was 
isolated from the gel and processed as described 
under Materials and Methods using 1 p.g 
Staphylococcus aureus V8 protease. After tricine~ 
SDS-PAGE film was exposed for 4 h. 
presence of 100 I'M T3, T4, rT3, iopanoic 
acid, 3,5-diiodotyrosine, thyronine or PTU 
(19), suggesting that the binding of BrAc-
[l25Iliodothyromnes to p32 does not 
represent the affimty-Iabeling of the 
substrate-binding site of ID-Ill. 
The prominent labeling of p32 in spleen 
and fetal liver microsomes despite their 
negligible ID-III activity (Fig. 1) further 
questions the possible relationship between 
p32 and ID-III. To exclude the possibility 
that the p32 labeled in brain and placenta is 
different from the p32labeled in spleen and 
fetal liver, the labeled proteins were 
excised from SDS-PAGE gels and analyzed 
by peptide-mapping using Staphylococcus 
aureus VB protease. This yielded identical 
radioactive peptide fragments in all four 
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tissues (Fig. 6). Peptide-mapping of p32 
from these same tissues using trypsin also 
gave rise to peptide fragments of identical 
size (results not shown). Therefore, p32 
appears to be identical in these different 
tissues. 
DISCUSSION 
Previous studies have demonstrated that 
BrAc[ 1251]T3 is an excellent affInity-label 
of ID-l (5,6). This was initially suggested 
by the flndings that reaction of rat liver 
microsomes with BrAcT3 resulted in the 
irreversible inactivation of ID-I, and that 
the concentration of BrAcT3 required for 
this inactivation was very low (= 0.1 nM) 
compared with the Km value for T3 (=10 
,aM) (5). Subsequent studies using SDS-
PAGE have shown that mainly two proteins 
are radioactively labeled by reaction of rat 
liver microsomes with BrAc[ 1251]T3, i.e. 
a =57 kDa protein (P57), which has been 
identified as PDI, and a =27 kDa protein 
(p27). Evidence that p27 represents ID-l or 
a subunit thereof can be summarized as 
follows. The labeling of p27 by 
BrAc[ 125I]iodothyronines a) is only 
observed in tissues with ID-l activity (Fig. 
1), b) is specifically inhibited by substrates 
and inhibitors of ID-I (6,27,28), c) is 
strongly correlated with ID-I activity under 
different pathophysiological conditions, 
such as starvation, hypothyroidism (29), 
and Se-deficiency (13,14,30), d) is strongly 
diminished in inbred mouse strains with ID-
I deflciency (11,12), e) is identical by size 
and peptide mapping with ID-I protein 
labeled with 75Se (13,14), f) corresponds 
closely with the MW of 29.7 kDa predicted 
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for ID-I by the rat ID-I cDNA nucleotide 
sequence (8), and g) is observed in cells 
transfected with ID-l cDNA but not in cells 
which do not express ID-I (31). The 
specific affinity-labeling of ID-I in tissue 
microsomal fractions despite the low 
deiodinase content (9) suggests an 
extremely high reactivity of the 
bromoacetyl group with an amino acid 
residue in the active center of ID-1. Since 
the high susceptibility of ID-l to 
inactivation by iodoacetate is explained by 
carboxymethylation of the Sec residue (32), 
it is tempting to speculate that the enzyme 
selenolate group is also the target for 
modification by BrAc-iodothyronines. 
However, the Sec126Cys mutant of ID-I is 
labeled as effectively by BrAc[I25I]T3 as 
the wild-type enzyme (31). Therefore, the 
molecular basis for this efficient affinity-
labeling of ID-I remains to be established. 
BrAc[ 125I]T4 has also been used to 
affinity-label ID-I1, resulting in the 
identification of a :=:::29 kDa substrate-
binding subunit of this multimeric protein 
(33). The 'fs'cifiC affinity-labelling of ID-ll 
by BrAc[ 1 51]T4 is not due to modification 
of a Sec residue. since there is strong 
evidence that ID-II is not a selenoprotein 
(30,34,35). 
Initial findings su~ested that the labeling 
of p32 by BrAc[ 1 I]T3 reported in the 
present and previous studies (19,36) 
represents the affinity-labeling of ID-ll!. 
The evidence for this hypothesis included 
a) the prominence of p32 in tissues such as 
brain, in particular fetal brain, and placenta 
with high ID-III activities (this paper,36), 
b) the close correlation between the 
progressive labeling of p32 and inactivation 
of ID-III by BrAcT3 with increasing 
Labeling of deiodinases with BrAc-iodothyronine derivatives 
reaction time or BrAcT3 concentration (this 
paper), and c) the inhibition of p32labeling 
and JD-Ill activity in rat placenta by I'M 
concentrations of goldthioglucose (GTG) 
(36). These GTG concentrations are much 
higher than the nM concentrations of GTG 
required for inhibition of ID~I activity, 
which is explained by the high reactivity of 
GTG towards the Sec residue in the latter 
enzyme (8,35,36). The relatively low 
susceptibility of JD-III to inhibition by 
GTG is in agreement with other evidence 
that JD-Ill is not a selenoprotein (37,38). 
However, there are major discrepancies 
which refute the possible relationship 
between p32 and JD-IIl, including a) the 
prominent labeling of p32 by BrAc[ 125I]T3 
in tissues such as spleen and fetal liver with 
very low JD-Ill activities (this paper ,36), b) 
the lack of p32 labeling by BrAc[ 125I]T3 
in embryonic chicken liver despite its high 
JD-Ill activity (19), c) the prominent 
labeling of p32 by the BrAe-derivative of 
[125I]rT3 which is not a substrate for JD-
III (this paper), d) the lack of inhibition of 
p32 labeling by BrAc[ 125I]T3 or 
BrAc[ 125I]rT3 in the presence of unlabeled 
substrates and inhibitors of JD-Ill far in 
excess of the concentrations producing 
cO~lete inhibition of the deiodination of 
[10 I]T3 (this paper,19,36). 
We conclude, therefore, that it is unlikely 
that the labeling of p32 by BrAc[ 125I]T3 
represents the affinity-labeling of JD-Ill. 
Although JD-Ill is inactivated by BrAcT3 
supposedly by covalent modification, we 
were unable to identify an alternative 
protein, the BrAc[ 125I]T3 labeling of 
which conforms to the tissue distribution 
and substrate competition expected for JD-
III. This may be due to the low abundance 
of ID-III even in rnicrosomes of placenta 
and fetal brain, which would make it 
undetectable in the presence of other 
prominently labeled proteins. Therefore, 
additional investigations are required for 
the unequivocal identification of JD-Ill by 
affinity-labeling. 
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Chapter 7 
At the start of the studies described in this thesis the identity of type I 
iodothyronine deiodinase (ill-I) was still to be determined. The enzyme had been 
identified with protein disulfide isomerase (PDI; 1-3), an abundant protein of the 
endoplasmic reticulum with a molecular mass of 56 kDa, but we considered this 
relation to be unlikely for various reasons. The reported protein concentration of PDI 
in liver microsomes (4,5) was much higher than the reported protein concentration 
of ill-I (6). Also, PDI had been shown to be a soluble acidic protein with a pi of 
.. 4.5 (7-9), whereas ill-I was found to be a transmembrane basic protein with a pi 
value of 9.3 in the delipidated state (10). Furthermore, a discrepancy was found in 
mRNA size as liver PDI is encoded by a 2.8 kb mRNA molecule (11), whereas ill-I· 
activity was induced inXenopus iaevis oocytes by injection of a polyadenylated liver 
RNA fraction of 1.5-2.0 kb (12). 
Closely followed by others (13,14), our group was the first to identify ill-I as the 
27 kDa protein labeled in rat liver microsomes by reaction with BrAc[ 125I]T 3. This 
identification, that is reported in Chapter 2, was done by showing selective inhibition 
ofiabeling of this protein in the presence of various substrates and inhibitors of ill-I. 
Furthermore, a very strong correlation was found between ID-I activity and labeling 
of the 27 kDa protein under widely varying conditions, such as trypsin treatment and 
procedures resulting in the stepwise removal of the various microsomal proteins. 
However, ill-I activity was not related to labeling of the 56 kDa PDI protein under 
any of the conditions tested. The finding that selenium deficiency leads to a decrease 
of ill-I activity and that the 27 kDa protein can be labeled with 75Se (15,16) further 
emphasized that ill-I and the 27 kDa protein are identical. Definitive prove came 
with the finding that ill-I is a selenocysteine-containing enzyme encoded by a mRNA 
of 2.1 kb from which a molecular mass of 29 kDa can be deduced (17). 
Several of the possible strategies to elucidate the structure of the ill-I gene 
required purified ill-I protein. However, purification was found to be very difficult 
(18-20) because of the physico-chemical properties of the enzyme (14) and its low 
abundance (6,21). Chapter 3 describes the multi-species comparison of liver ill-I 
carried out to investigate possible other sources for the purification of the enzyme 
and to detect possible interspecies differences. Because the elucidation of the human 
ill-I gene was a major goal, it was not desirable to purify ill-I from a species 
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displaying characteristics widely different from human ID-I as this might indicate a 
low genetic homology between the two ID-I genes. 
ID-Iwas characterized by evaluation of rT3 ORD activity in liver microsomes and 
by affinity-labeling of microsomal proteins with BrAc[125I]T3. Using SDS-PAGE 
and autoradiography, ID-I was identified and subsequently quantified by saturation 
analysis of the progressive labeling with increasing BrAcT3-concentrations. BrAcT3 
was found to be an effective affinity-label for ID-I from different species and a 
narrow range was found for subunit Mr (25.7-29.1 kDa). Hepatic microsomal ID-I 
content varied significantly between the studied species, with dog and rat displaying 
the highest levels. The latter species also displayed highest ID-I activity. The 
turnover number of dog liver ID-I, using rT3 as substrate, was found to be 
exceptionally low compared to the other species investigated. Labeling of dog liver 
ID-Iby BrAc[125I]T3 was not completely prevented by the presence oflO,uM rT3 
plus 100,uM PTU, in contrast with the other species. These data suggest a high 
degree of homology for ID-I subunit structure between the various species. However, 
substrate specificity of dog ID-I is remarkably different. Others have also found dog 
ID-I to be considerably different from the rat liver enzyme with respect to substrate 
preferences (22). 
Preceded by the elucidation of the genetic sequence of rat (17) and human (23) ID-
I, dog ID-I was recently cloned in order to identify the amino acid residues critical 
for rT3 binding by comparative analysis of function versus structure (24; Fig. 1). It 
was found that the KID for rT3 deiodination of the dog enzyme was 25-fold higher 
than that of the human enzyme, whereas the Km for T4 deiodination was only 3-fold 
higher in dog. This suggests that the differences between ID-I in these species affect 
rT3 binding more than that of T4. Using mutational studies it was shown that only 
three of the amino acid substitutions are mainly responsible for the observed 
differences in substrate preferences between human and dog ID-I. Replacement of 
these residues in dog ID-I with those of human ID-I yields an enzyme displaying 
human type characteristics and vice versa. 
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Figure 1. Alignment of the predicted amino acid sequences of human, rat and dog type 
I deiodinases. For the sequences of the rat and dog enzymes, only those 
residues that are different from the human enzyme are shown; residues identical 
to the human enzyme are indicated by dots. The dashes indicate amino acids 
which are not present in the dog enzyme. Selenocysteine at position 126 is 
shown with an asterisk (taken from Ref. 24). 
Various inbred mouse substrains differ markedly in hepatic deiodinase activity. 
Most mice of the C3H/He (C3H) substrain were found to be almost devoid of liver 
ID-I activity, whereas highly variable enzyme activities were found in the other 
animals. Chapter 4 reports the first full description of a defect in ID-I activity in an 
animal strain. A strong correlation was found between ID-I activity, labeling of the 
28 lcDa ID-I protein, and ID-I mRNA levels in animals of both C3H and C57BL/6N 
(C57) substrains. This suggests that the low ID-I activity in C3H mice is due to a 
decrease in transcription of the ID-I gene or reduced stability of the mRNA. 
Selenium deficiency resulted in a decrease of ID-I activity in both mouse substrains. 
After [15Sej-selenite injection, it was found that incorporation of 75Se in ID-I was 
higher in Se-deficient than in control mice and was also higher in C57 than in C3H 
94 
General discussion 
mice, suggesting that mouse ID-I is a selenoprotein like rat, human and dog ID-I 
(24). 
As ID-I plays a key role in thyroid hormone metabolism and specifically is 
responsible for the largest part of peripheral T 3 production, it was surprising that T 4 
and T 3 levels in the circulation of affected C3H animals were found to be normal 
although the serum rT 3 concentration was elevated. These findings are in contrast 
with a recent publication of Berry et al. (25) in which the decrease of ID-I activity 
in C3H mice was accompanied by an increase in serum T4' Furthermore, their 
population of over 40 C3H mice displayed a homogeneously decreased level of ID-I 
activity opposed to the extremely variable enzyme activity found in our animals. 
Animals from both studies originated from the same supplier, The Jackson 
Laboratory (Bar Harbor, ME). However, the animals used in our investigations were 
at least 8 weeks old whereas the mice used in the study of Berry et al. were 
sacrificed at 7 weeks. Perhaps this difference in age can account for the observed 
discrepancies. 
The segregation characteristics of ID-I in inbred strains, derived from crosses 
between high and low ID-I activity strains, suggested a single allele difference (25). 
Furthermore, a restriction fragment length variant that segregated with ID-I activity 
was observed on Southern blots using a rat ID-I probe. Using recombination 
frequencies for previously mapped loci, the ID-I gene was assigned to mouse 
chromosome 4 and its approximate chromosomal position was determined. Because 
this region of mouse chromosome 4 was found to be homologous to a region of 
human chromosome 1 and these regions display uninterrupted conserved linkage, the 
ID-I gene was predicted to be located on human chromosome 1 (25). 
Although T3 is not the preferred substrate ofID-I, BrAc[1251]T3 has proven to be 
an excellent affinity-label of this enzyme (6,13,14; Chapters 2-4). This was also 
evident from the very low apparent I<j as revealed by Lineweaver Burk analysis 
( "" 0.1 nM) (6), compared with the Km value for T3 ("" 1 0 ,uM) or even the 
preferred substrate rT3 (""O.l,uM) (26). Using N-AcT3, it was found that 
introduction of the acetyl group already caused a decrease in the I<j of T 3 to 
"" 0.1 ,uM, which is in agreement with the observed decrease in I<j of other 
iodothyronines upon N-acylation (6). Although ID-I content in the microsomal 
fraction is very low (23), the enzyme is labeled and inactivated by BrAcT3 in a 
higbly specific manner. This suggests an extremely high reactivity of the 
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bromoacetyl group with an active center amino acid residue. A possible candidate 
would be the selenocysteine residue, thought to be responsible for the high 
susceptibility of ID-I to inactivation by iodoacetate by carboxymethylation (27). 
However, replacement of this residue by a normal cysteine residue, using site-
directed mutagenesis, did not result in a decrease of labeling efficiency (28). 
Therefore, the molecular mechanism of the efficient affinity-labeling of ID-I remains 
to be elucidated. 
In addition to the "" 27 kDa and "" 56 kDa proteins, another prominent band with 
Mr of 32 kDa was observed after labeling of pig liver microsomes with 
BrAc[125I]T3 in the multi-species comparison ·of ID-I. The hypothesis that this 32 
kDa band might represent the type III iodothyronine deiodinase (ID-III) seemed to 
be supported by the following observations: 1) significant ID-III activity is found in 
pig liver microsomes in contrast to rat, 2) a 32 kDa band is also seen in labeling 
patterns of rat brain and placenta microsomes that contain very high ID-III activities, 
3) reaction with BrAcT 3 results in rapid and irreversible inactivation of ID-III, and 
4) a good correlation can be found between the extent oflabeling of the 32 kDa band 
and the extent of inactivation of ID-III, both in a dose and time dependent manner. 
In Chapters 5 and 6, it is shown to be very unlikely that the 32 kDa protein and 
ID-III are identical, because 1) labeling of the 32 kDa protein is observed not ouly 
in tissues with high ID-III activity such as rat brain and placenta, but also in tissues 
lacking enzyme activity such as rat spleen and fetal liver , 2) it was shown by peptide 
mapping that this labeled protein is identical in all these organs, 3) labeling with 
BrAc[ 125I]T 3 yields no 32 kDa band in embryonic chicken liver microsomes, in· 
which ID-III activity shows similar levels and characteristics as rat placenta, and is 
as sensitive to iulnbition by BrAcT3 as rat ID-III, 4) although rT3 is not a substrate 
for ID-III, the 32 kDa protein is readily labeled by BrAc[l25I]rT 3, 5) labeling of the 
32 kDa band by both BrAc[125I]T3 or BrAc[125I]rT3 is not influenced by 100 I'M 
concentrations of substrate analogs or inhibitors of ID-III, although some of these 
substances inhibit ID-III activity almost completely at 100-fold lower concentrations. 
Part of these results were presented at the 19th annual meeting of the European 
Thyroid Association, August 25-30 1991, Hannover, Germany (29). After this 
presentation Santini et al. submilled a study in which they reported similar findings 
concerning the inactivation of ID-III as well as the labeling of a 31 kDa protein with 
BrAcT 3 in rat placental microsomes (30). They proposed that this 31 kDa protein 
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is the substrate-binding subunit of ID-ill, although labeling of this protein was 
inhibited only partially by the presence of 150 pM T 3 and was also found in tissues 
devoid of ID-ill activity. However, we strongly doubt that the 31-32 kDa protein 
represents ID-ill or a subunit thereof. 
In order to get a better understanding of the structure and catalytic mechanism of 
IDa, future investigations could concentrate on the identification of the amino acid 
residues which are involved with" the binding of the substrate or which participate in 
the deiodination process in a direct manner. It will also be interesting to find out 
which residues are responsible for the inactivation of ID-I by BrAcT 3 or PTU. 
Furthermore, until now it has not been proved that ID-I is indeed a homodimer of 
two 27 kDa subunits, as has been assumed. Such evidence could be provided by 
cross-linking experiments combined with label-incorporation studies using 
BrAc[ 125I]T 3 and 75Se. 
Future research might also focus on the elucidation of the genetic structure of ID-
ill. Possibly the Xenopus laevis oocyte expression system can provide the means to 
clone and investigate this enzyme. Recently the cDNA of a tadpole protein displaying 
characteristics of ID-ill has been cloned and sequenced (31). Maybe, this cDNA can 
be used to characterize human ID-ill. However, it has not been established if the 
cDNA cloned from Xenopus laevis represents the tadpole equivalent of mammalian 
ID-ill or an evolutionary divergent form of ID-I with prevalent inner ring deiodinase 
activity. 
The type I and ill iodothyronine deiodinases are unique enzymes, playing major 
roles in thyroid hormone metabolism. Their activity is influenced by hypo- or 
hyperthyroidism and may be altered in pathophysiological conditions, such as 
starvation or non-thyroidal illness. Furthermore, the action of ID-I may be affected 
by drugs such as dexamethasone, propranolol, amiodarone and PTU. Knowledge of 
the catalytic mechanism and molecular structure of these enzymes is crucial for 
better understanding of their role in the regulation of thyroid hormone bioactivity. 
It may lead to the development of more potent and specific inhibitors of ID-I, which 
are potential drugs in the treatment of hyperthyroidism. 
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Summary 
This thesis describes research on the enzymes responsible for deiodination of 
thyroid hormones or iodothyronines. In humans the tbyroid secretes predominantly 
the prohormone thyroxine (T4)' Active thyroid hormone is generated when T4 is 
converted to 3,3' ,5-triiodothyronine (T3) by removal of an iodine atom. This 
deiodination is catalyzed by so called iodothyronine deiodinases - enzymes also 
capable of catalyzing other deiodination steps, resulting in tbe generation of the 
various otber iodothyronines. 
Next to a general introduction, Chapter 1 gives an overview of the current state of 
knowledge concerning tbe characterization of the three different types of deiodinases 
discovered until now. Furthermore, alternative metabolic routes for iodothyronines 
are discussed, together with their transport from the plasma to their target tissues and 
the molecular mechanism of action of tbyroid hormone involving different thyroid 
hormone receptors and response elements. 
The study described in Chapter 2 resulted in the unambiguous identification of type 
I iodotbyronine deiodinase (ID-I). The study was undertaken to test the hypothesis 
put forward by others in a previous publication that ID-I was identical to protein 
disulfide isomerase (PDI). When rat liver microsomes were labeled by N-
bromoacetyl-[125I]T3 (BrAc[125I]T3) and subsequently separated by SDS-PAGE, 
two prominently labeled bands with relative molecular mass (Mr) of 56 and 27 kDa 
were seen on tbe autoradiogram of the gel. Labeling of the 27 kDa band, but not that 
of the 56 kDa band, was inhibited by substrates and inhibitors of ID-I. Trypsin 
treatment of microsomes resulted in elimination of both labeling of the 27 kDa 
protein and ID-I activity. However, labeling of the 56 kDa protein was not 
diminished by trypsinization. After treatment of microsomes with carbonate buffer 
of pH 8.0-9.5 or witb 0.05 % deoxycholate both PDI content and labeling of the 56 
kDa protein were strongly diminished, whereas ID-I activity and labeling of the 27 
kDa protein were uninfluenced. Above pH 10 the latter two decreased in parallel. 
Although rat pancreas microsomes contained high concentrations of PDI, they 
showed no ID-I activity. Upon BrAcT3-labeling of these microsomes a strong 56 
kDa band was seen, whereas nO 27 kDa protein was labeled. Purified PDI with Mr 
of 56 kDa displayed no ID-I activity but was readily labeled witb BrAcT3' These 
results prove that the 27 kDa band represents ID-I and, thus, that PDI is not identical 
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to ID-I. 
Purification of ID-I from the membranous fraction of liver or kidney has proven 
to be very difficult because it is an extremely hydrophobic transmembrane protein 
that is present in very low concentrations. In the study described in Chapter 3, ID-I 
was investigated in liver microsomal fractions of different species to explore 
alternative sources for purification of this enzyme and to elucidate possible 
interspecies differences. ID-I was characterized by measurement of its activity using 
the preferred substrate 3,3' ,5' -triiodothyronine (rT3) and by affinity-labeling with 
BrAc[125I]T3. ID-I was identified and quantified using SDS-PAGE and 
autoradiography. In the species studied the Mr ofID-I varied between 25.7 and 29.1 
kDa. Liver microsomes from rat and dog displayed a markedly higher ID-I content 
than liver microsomes from human, mouse, rabbit, cow, pig, sheep, goat, chicken 
or duck. Rat liver microsomes showed highest ID-I activity of all species examined. 
Turnover numbers for ID-I, for all species except dog, varied between 264 and 1059 
min-1 with rabbit and goat displaying highest values. Dog liver microsomal ID-I 
displayed an exceptionally low turnover number of 79 min-1 and, unlike the other 
species, labeling of the enzyme could not be prevented by 10 ,uM rT3 plus 100,uM 
6-N-propyl-2-thiouracil (PTU). From these results it was concluded that ID-I has 
similar properties in all species investigated with exception of dog. 
The interspecies comparison of ID-I had included the BALB/c mouse strain. 
However, large differences in ID-I activity were found between different mouse 
strains, with substrain C3H/He (C3H) displaying an exceptionally diminished ID-I 
activity compared with BALB/c and C57BL/6N (C57) mice. In the experiments 
reported in Chapter 4 it was investigated if this diminution correlates with the results 
of labeling experiments with BrAc[ 125I]T 3 or 75Se. By this time it was found by 
others that ID-I in rat and human is a selenoenzyme that can be labeled by 
radioactive selenium. ID-I activity in liver microsomes of C3H mice was found to 
be highly variable with a median of only 18 % of that found in C57 mice. 
Surprisingly, T4 and T3 levels in the circulation were normal, although the serum 
rT3 concentration was elevated. Mouse ID-I with a Mr of 28 kDa was identified on 
autoradiograms of BrAc[125I]T3 labeled microsomes analyzed by SDS-PAGE. 
Labeling of the 28 kDa band was nearly absent in C3H samples with low ID-I 
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activity. In Se-deficient mice both ID-l activity and labeling of the 28 kDa band was 
strongly decreased compared to control mice. Labeling of ID-l with 75Se was 
demonstrated by SDS-PAGE of liver microsomes isolated from C5Sej-selenite 
injected mice. Labeling of ID-l with 75Se was clearly higher in Se-deficient than in 
Se-sufficient mice and was also higher in C57 than in C3H mice. Using a rat ID-l 
cDNA probe, liver ID-l mRNA was quantified on Northern blots. It was found that 
mRNA concentrations correlated strongly with ID-l activity and that both were 
strongly decreased in most C3H mice. From these results it is concluded that lD-I 
in mouse is also a selenoenzyme. ID-l activity in C3H mice is decreased because of 
diminished transcription of the ID-l gene or reduced stability of the mRNA. 
In the multi-species comparison in Chapter 3 it was noticed that BrAcT3-labeled 
pig liver microsomes showed, next to the ID-l band of 27.6 kDa, a very strongly 
labeled band of "" 32 kDa. The possibility that this band might represent the type III 
iodothyronine deiodinase (ID-III) was supported by the findings that pig liver 
microsomes show high ID-III activity compared to rat, and that a 32 kDa protein is 
labeled in microsomes of rat brain and placenta, both displaying high ID-III activity. 
This possibility was further investigated as described in Chapter 5. ID-III activity in 
microsomes of rat brain, rat placenta and embryonic chicken liver is inhibited in an 
irreversible manner by BrAcT3 with an affinity similar to that of T3. Reaction with 
BrAc[ 125I]T 3 resulted in the labeling of a 32 kDa band in microsomes of rat brain 
and placenta, but also in fetal rat liver microsomes that had no ID-III activity. 
Labeling of the 32 kDa band was not influenced by the presence of 100 I'M 
concentrations of substrate analogs or inhibitors of ID-III, whereas some of these 
substances inhibited ID-III activity almost completely at 1 I'M. Embryonic chicken 
liver microsomes showed high ID-III activity, but upon labeling with BrAc[125I]T3 
no 32 kDa band could be demonstrated nor another protein possibly representing lD-
III. From these results it is concluded that it is unlikely that the labeled 32 kDa 
protein is identical to ID-III or a subunit thereof. 
Chapter 6 describes investigations in which the prevalence of the different types 
of deiodinases in various rat tissues was compared to the labeling patterns obtained 
when subfractions of these organs were reacted with N-bromoacetyl-
[l25ljiodothyronine derivatives. This was done to find out if ID-III could be 
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identified by affinity-labeling with these substances. It was found that microsomes 
from rat kidney, liver and thyroid contained high ID-I activity and after reaction with 
BrAc[ 125I]T 3 showed a prominent band of 27 kDa in their labeling pattern. Rat 
brain and placenta microsomes displayed high ID-rn activity and a band of 32 kDa 
upon affinity-labeling with BrAc[12SI]T3. The finding that ID-III was readily 
inactivated by reaction with BrAcT 3 indicated that this substance might be a useful 
affinity-label for the identification of this enzyme. A good correlation was found 
between the extent of labeling of the 32 kDa band and the extent of inactivation of 
ID-III. Treatment of rat brain or placenta microsomes with O.OS % deoxycholate or 
carbonate buffer of pH 11.S rod not eliminate labeling of the 32 kDa band, indicating 
a transmembrane localization of this protein. The 32 kDa protein was readily labeled 
by BrAc[12SI]rT3' although rT3 is not a substrate for ID-III. Labeling of rat brain 
microsomes with this affinity-label was uninfluenced by the presence of 100,uM 
concentrations of different iodothyronines. However, deiodination of [l25I]T 3 by the 
same microsomes was reduced by 91 and 96 % by 1 ,uM T4 and T3, respectively. 
A 32 kDa band was also found in the labeling patterns of spleen and fetal liver 
microsomes, although neither preparation shows ID-rn activity. Peptide mapping of 
the 32 kDa band from brain, placenta, spleen and fetal liver microsomes resulted in 
identical fragments in all four tissues, indicating that the labeled protein is identical 
in these cases. These results once more strongly suggest that the identity of ID-III 
has not been elucidated until now. 
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Samenvatting 
In dit proefschrift wordt onderzoek beschreven dat verricht is aan de enzymen die 
verantwoordelijk zijn voor de dejodering van schildklierhormonen oftewel 
jodothyronines. De humane schildklier scheidt voomamelijk het prohormoon 
thyroxine (T4) uit. Actief schildklierhormoon ontstaat pas wanneer T4 door het 
verwijderen van een jodium atoom, oftewel dejodering, wordt omgezet in 3,3',5-
trijodothyronine (T3)' Deze dejodering wordt gekatalyseerd door zogenaamde 
jodothyronine dejodasen - enzymen die naast voomoemde omzetting ook nog andere 
dejoderingsstappen kunnen bewerkstelligen en daarmee verantwoordelijk zijn v~~r 
de vorming van de verschillende jodothyronines. 
Naast een algemene inleiding, wordt in Hoofdstuk 1 een overzicht gegeven van de 
huidige stand van zaken betreffende de karakterisering van de drie verschillende 
typen dejodasen die tot op heden zijn aangetoond. Verder komen altematieve 
afbraakroutes van jodothyronines aan bod, samen met hun transport vanuit het 
plasma naar de doelweefsels, het moleculaire werkingsmechanisme van 
schildklierhormoon en de verschillende schildklierhormoon receptoren en respons 
elementen die hierbij betrokken zijn. 
De studie die wordt beschreven in Hoofdstuk 2 resulteerde in de onomstotelijke 
identificatie van het type I jodothyronine dejodase (ID-I). Kort daarvoor was 
namelijk door anderen in de literatuur beweerd dat het enzym protein disulfide 
isomerase (PDI) identiek aan ID-I was. Wanneer microsomale ratte lever eiwitten 
gelabeld werden met N-bromoacetyl-[125I]T3 (BrAc[125I]T3) en vervolgens 
gescheiden werden met SDS-PAGE, werden op het autoradiogram van de gel (wee 
prominentgelabelde banden waargenomen met relatieve molecuulmassa's (Mr) van 
56 en 27 kDa. Substraten en inhibitoren van ID-I waren in staat om de labeling te 
remmen van de 27 kDa band maar niet die van de 56 kDa band. Behandeling van 
microsomen met trypsine resulteerde in het uitblijven van labeling van het 27 kDa 
eiwit en het verdwijnen van ID-I activiteit, terwijl de labeling van het 56 kDa eiwit 
niet geremd werd. Na behandeling van microsomen met carbonaat buffers van 
pH 8.0-9.5 of met 0.05 % deoxycholaat waren zowel het PDI gehalte als de labeling 
van het 56 kDa eiwit sterk afgenomen terwijl de ID-I activiteit en labeling van het 
27 kDa eiwit niet verminderden. Boven pH 10 namen de laatste twee grootheden 
parallel af. Ratte pancreas microsomen bevatten hoge concentraties PDI maar 
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vertoonden geen ID-I activiteit. Wanneer deze microsomen gelabeld werden met 
BrAc[125I]T3 resulteerde dit in een zeer sterke labeling van een 56 kDa eiwit terwijl 
geen 27 kDa eiwit kon worden waargenomen. Gezuiverd PDI met een 
molecuulmassa van 56 kDa werd uitstekend gelabeld door BrAcT 3 maar vertoonde 
geen ID-I activiteit. Deze resultaten bewijzen dat de 27 kDa band ID-I representeert 
en dat derhalve PDI en ID-I verschillende eiwitten zijn. 
De zuivering van ID-I uit de membraanfractie van lever of nier is zeer moeilijk 
gebleken doordat het hier een nitermate slecht oplosbaar transmembraan eiwit betreft 
dat in zeer lage concentraties voorkomt. In de experimenten beschreven in 
Hoofdstuk 3 wordt ID-I in microsomale lever fracties van verschillende species 
onderzocht om mogelijke alternatieve bronnen v~~r de zuivering van dit enzym aan 
het licht te brengen en om eventuele interspecies verschillen te onthullen. ID-I werd 
gekarakteriseerd met activiteitsmetingen met het geprefereerde substraat 3,3',5'-
trijodothyronine (rT3) en door affiniteits-labeling met BrAc[125I]T3' Gelabelde ID-I 
werd geidentificeerd en gekwantificeerd met SDS-PAGE en autoradiografie. In de 
bestudeerde species varieerde het Mr van ID-I tussen 25.7 en 29.1 kDa. Ratte en 
honde lever microsomen vertoonden een opvallend hoger enzym gehalte dan de lever 
microsomen van mens, muis, kouijn, koe, varken, schaap, geit, kip of eend. Ratte 
lever microsomen vertoonden de hoogste ID-I activiteit van aile onderzochte species. 
De omzettingssnelheid van ID-I lag voor aile species, behalve de hond, tussen 264 
en 1059 min-1 waarbij konijn en geit de hoogste waarden vertoonden. Honde lever 
microsomaal ID-I vertoonde de uitzonderlijk lage omzettingssnelheid van 78 min-1 
en labeling van het eiwit bleek, in tegenstelling tot de andere species, slecht rembaar 
met 10,uM rT3 plus 100,uM 6-N-propyl-2-thiouracil (PTU). Uit deze gegevens is 
af te leiden dat ID-I gelijksoortige eigenschappen bezit in aile bestudeerde species 
met uitzondering van de hond. 
Bij de interspecies vergelijking van ID-I was de BALB/c muize stam betrokken. 
Tussen de verschillende substammen werden echter grote verschillen gevonden in 
ID-I activiteit. Hierbij bleek de substam C3H/He (C3H) een uitzonderlijk lage ID-I 
activiteit te vertonen ten opzichte van BALB/c en C57BL/6N (C57) muizen. In 
Hoofdstuk 4 wordt onderzocht of deze verlaging correleert met de resultaten van 
labelingsexperimenten met BrAc[ 125I]T 3 of 75Se. Ondertussen was namelijk door 
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anderen bekend geworden dat ID-I in rat en mens een seleno-enzym is dat met 
radioactief selenium gelabeld kon worden. ID-I activiteit in lever microsomen van 
C3H muizen bleek in hoge mate variabel met een mediaan van slechts 18 % van die 
gevonden in C57 muizen. De serum T4 en T3 concentratie van C3H muizen was 
echter normaal, alhoewel het serum gehalte aan rT3 verhoogd was. Muize ID-I met 
een Mr van 28 kDa werd geldentificeerd met behulp van SDS-PAGE van 
BrAc[125I]T3 gelabelde lever microsomen. In C3H monsters met lage ID-I activiteit 
was deze labeling zo goed als afwezig. De ID-I activiteit was sterk veriaagd in Se-
deficiente muizen, wat vergezeld ging met een drastische afname van de labeling van 
de 28 kDa band vergeleken met controle muizen. Labeling van ID-I met 75Se kon 
worden aangetoond met SDS-PAGE van lever microsomen gelsoleerd uit e5Se]-
seleniet gelnjecteerde muizen. 75Se labeling was duidelijk hoger in Se-deficiente dan 
in Se-sufficiente muizen en was ook duidelijk hoger in C57 dan in C3H muizen. 
Lever ID-I mRNA werd gemeten op Northern blots met gebruikmaking van een ratte 
ID-I cDNA probe. Hieruit bleek dat de concentratie aan mRNA in sterke mate 
correleerde met de ID-I activiteit en dat beiden relatief laag waren in de meeste C3H 
muizen. Vit deze resultaten voigt dat ID-I ook in de muis een seleno-enzym is. 
Verder is de ID-I activiteit in C3H muizen relatief laag door een lage transcriptie van 
het ID-I gen of door een geringe stabiliteit van het mRNA. 
In de multi species vergelijking in Hoofdstuk 3 viel het op dat in BrAcT 3-gelabelde 
varkens lever microsomen, naast de ID-I band van 27.6 kDa, ook een band van 
",32 kDa zeer sterk gelabeld werd. De mogelijkheid dat deze band het type III 
jodothyronine dejodase (ID-III) representeerde leek aanwezig, omdat varkens lever 
microsomen een verhoogde ID-III activiteit vertoonden vergeleken met de rat en 
omdat ook een 32 kDa eiwit gelabeld werd in microsomen van ratte hersenen en 
placenta die beiden een hoge ID-III activiteit bezaten. Deze mogelijkheid werd verder 
onderzocht in het onderzoek dat beschreven is in Hoofdstuk 5. De ID-III activiteit 
in ratte hersenen, ratte placenta en embryonale kippe lever werd irreversibel geremd 
door het affiniteits-Iabel BrAcT3 met een affiniteit vergelijkbaar met die van T3' 
Reactie van ratte hersen en placenta microsomen met BrAc[125I]T 3 resulteerde in 
sterke labeling van een 32 kDa eiwit. Dit eiwit werd echter ook gelabeld in foetale 
ratte lever microsomen die geen ID-III activiteit hadden. De labeling van de 32 kDa 
110 
Samenvatting 
band werd niel beinvloed door de aanwezigheid van 100 ,uM concenlralies van 
subslraal analoga of remmers van ID-III lijdens de labelingsreaclie, lerwijl sommige 
van deze stoffen de ID-III activiteil nagenoeg volledig remden bij een concentralie 
van 1 ,uM. Wanneer embryonale kippe lever microsomen, mel een hoge ID-III 
aclivileil, gelabeld werden mel BrAc[125I]T3 werd geen 32 kDa eiwil waargenomen 
noch enig ander eiwit dal mogelijk hel ID-III represenleert. Gezien deze bevindingen 
is hel onwaarschijniijk dal hel 32 kDa eiwil idenliek is aan hel ID-III of een subunil 
hiervan. 
In Hoofdsluk 6 wordl onderzoek beschreven waarin de prevalenlie van de 
verschillende typen dejodasen in diverse ratte weefsels vergeleken werd met de 
labelingspatronen die verkregen werden na reactie van subfracties van deze weefsels 
mel N-bro~oacelyl-[125I]jOdolhyronine derivalen. Hel doel hiervan was om Ie 
achlerhalen of ID-III geldenlificeerd kon worden door affiniteits-labeling mel deze 
subslanlies. Hel bleek dal nier, lever en schildklier microsomen een hoge ID-I 
aclivileil bezaten, terwijl hersen en placenta microsomen een hoge ID-III activiteit 
vertoonden. Na labeling met BrAc[125I]T 3 kon een prominenle band van 27 kDa 
gezien worden in het labeJingspatroon van de weefsels met hoge ID-I activiteit. In 
de organen die een hoge ID-III activiteil vertoonden werd een band van 32 kDa 
gelabeld. De bevinding dat ID-III snel gelnactiveerd werd door reactie met BrAcT 3 
gaf aan dat deze subslanlie mogeJijk een brnikbaar affiniteils-label was voor de 
identificatie van dit enzym. Een goede correlatie werd gevonden tussen de male van 
affinileils-labeJing van de 32 kDa band mel BrAc[125I]T3 en de male van 
inactivering van ID-Ill. Na behandeJing van ratte hersen ofplacenla microsomen mel 
0.05 % deoxycholaal of carbonaal buffer van pH 11,5 werd nog sleeds een 32 kDa 
eiwit gelabeld door BrAc[ 125I]T 3, wal aangaf dal hel eiwil een Iransmembraan 
lokalisatie had. Alhoewel rT3 geen substraal is voor ID-III werd hel 32 kDa eiwil 
uitslekend gelabeld door BrAc[125I]rT3. De labeling van hel 32 kDa eiwil in ratte 
hersen microsomen mel dil affinileits-label werd op geen eukele manier belnvloed 
door de aanwezigheid van 100 ,uM concentraties van verschillende jodolhyronines 
met PTU. De dejodering van [125I]T3 door ID-III in dezelfde microsomen werd 
echter voor 91 en 96 % geremd door respectievelijk 1 ,uM T4 en T3. Labeling van 
een 32 kDa band werd ook gevonden in microsomen van milt en foetale lever die 
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echter geen van beiden ID-ill activiteit vertoonden. Peptide mapping van de 32 kDa 
band uit hersen, placenta, milt en foetale lever microsomen resulteerde in identieke 
fragmenten in aile vier weefsels, wat aangeeft dat het gelabelde eiwit in aile gevallen 
identiek is. Vit deze resultaten voIgt wederom dat de identiteit van ID-III nog 
definitief vastgesteld moet worden. 
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Het moge duidelijk zijn dat een proefschrift niet een weerspiegeling is van het 
werk van een maar van vel en. Daarom wi! ik hierbij een ieder die direct dan weI 
indirect heeft bijgedragen aan de totstandkoming van dit proefschrift oprecht danken. 
Vanaf het begin dat ik, als broekie, binnenkwam op de Afdeling Interne III ben ik 
geaccepteerd en gewaardeerd; niet alleen door de staf maar door alle medewerkers. 
Hierdoor heb ik altijd met veel plezier deel uitgemaakt van deze groep en beschouw 
ik deze periode met een warm gevoel in mijn hart. Van de vele betrokkenen wi! ik 
de hieronder genoemde personen in het bijzonder danken. 
Mijn promotor Prof.Dr.Ir. Visser: Beste Theo, Ik wil je danken voor de 
uitstekende begeleiding tijdens ons onderzoek. Iij maakte en maakt altijd tijd om 
samen te filosoferen over allerlei theorieen om de resultaten van onderzoek te 
verklaren. Ondanks je eigen superioriteit, sta je hierbij altijd open voor wat voor 
ideeen dan ook en treedt je anderen tegemoet op basis van gelijkheid, waardoor de 
sfeer optimaal is en blijft. Tijdens het schrijven van de artikelen en dit boekje was 
het voor mij een heel geruststellend idee dat je het nog na zou kijken, want in plaats 
van schrijven componeer jij artikelen. 
Dr. Docter: Beste Roel, Door de goede infra-structuur binnen jouw lab was het 
mogelijk om op een efficiente manier onderzoek te doen; iets dat lang niet altijd 
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sporten. Ook voor uw steun bij het aangaan van mijn huidige opleiding tot klinisch 
chemicus ben ik u dank verschuldigd. 
Prof. Dr. Krenning: Beste Eric, Het klinkt misschien raar maar vooral door jou, 
als hoofd van de Afdeling Nucleaire Geneeskunde en tegelijk lid van de schildklier-
groep, werd ik bewust van de sterke band binnen deze groep. Als nieuwe chemie-
eend werd ik door jou vanaf het begin zonder vragen geaccepteerd en opgenomen 
in de bijt. Ik dank je voor het creeren van optimale omstandigheden voor team-geest 
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reserveren om een enigszins passend dankwoord te formuleren. Terwijl ik bezig was 
om te proberen doorbraken in het onderzoek te forceren op manieren waarvan de 
kans op succes ondllidelijk was, heb jij op een gedegen manier de fundering voor dit 
proefschrift gelegd. Verder is een groot deel van de gebruikte bouwstenen afkomstig 
van jouw hand. AI was het experiment nog zo groot, jij slaagde erin om het op een 
reproduceerbare manier tot een goed einde te brengen en verzorgde de perfecte 
documentatie van de resultaten. 
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